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 
ABSTRACT 
 
Isoflavonoids are naturally occurring plant derived biochemicals, which act as 
phytoalexins. Isoflavonoids are of interest due to their estrogenic and other potential 
physiological properties, particularly in mammals that typically consume isoflavonoid 
rich nutrients such as soy and red clover.  
 
The literature review of this thesis mainly focuses on the reduced metabolites of 
hydroxy and/or methoxy substituted isoflavones with four groups: isoflavan-4-ols, 
isoflav-3-enes, isoflavans and -methyldeoxybenzoins (1,2-diarylpropan-1-ones), 
which are all reduced metabolites of food derived isoflavones in mammals. Related 
isoflavan-4-ones are briefly discussed. Results of an extensive survey of the literature 
concerning the synthesis of polyhydroxy- or methoxysubstituted  isoflavonoids and 
especially asymmetric approaches are discussed.  
 
 
The experimental section describes new synthetic methods to prepare polyphenolic 
reduced isoflavonoid structures such as isoflav-3-enes, isoflavan-4-ones, cis- and 
trans-isoflavan-4-ols, 1,2-diarylpropan-1-ones and isoflavans by various hydride 
reagents and hydrogenations. The specific reactivity differences of various hydride 
reagents toward isoflavonoids are discussed. 
 
The first enantioselective synthesis of natural (S)-(-)-equol and the opposite 
enantiomer (R)-(+)-equol is also described by the asymmetric iridium PHOX 
catalysed hydrogenation of isoflav-3-enes. Both of these equol enantiomers are found 
to possess biological activity in mammals due to estrogen receptor binding activity. 
The natural enantiomer prefers estrogen receptor  and the R-enantiomer prefers the 
estrogen receptor . Also the precursor, isoflav-3-ene, is found to possess positive 
biological effects on mammals. In connection with the synthetic work, the (S)-(-)-
equol was discovered from serum of ewes after isoflavone rich red clover feeding. 
The chiral HPLC method was developed to identify natural equol enantiomer for the 
first time in this species. 
 
The first synthesis of natural isoflavonoid (R)-(-)-angolensin and its enantiomer (S)-
(+)-angolensin is desribed by the use of recyclable chiral auxiliaries (chiral 
pseudoephedrines). The method offers a general approach also to other natural 
polyphenolic 1,2-diarylpropan-1-ones and to further study isoflavonoid metabolism in 
human and other mammals. 
 
The  absolute configurations of these new chiral isoflavonoid metabolites were 
determined by X-ray spectroscopy. Also thorough NMR and MS analysis of 
synthesised structures are presented. 
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 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1. INTRODUCTION 
 
  
Isoflavonoids are naturally occurring plant derived biochemicals, which act as 
phytoalexins against bacteria, viruses and insect pests in flora. Isoflavonoids 1- 13 are 
a subclass of the taxonomically more widely occurring phytochemicals, flavonoids 
(flavone 14), both posessing a phenylchroman skeleton of 15 carbon atoms (Fig. 1). 
Isoflavonoids differ from flavonoids by the position of phenyl ring B, which is in the 
C-3 position instead of C-2 as in flavonoids. Isoflavonoids are of interest due to their 
estrogenic and other potential physiological properties, particularly in mammals that 
typically consume isoflavonoid rich nutrients.  
 
The work described in this thesis was entirely focused on the isoflavonoids, especially 
the reduced metabolites of hydroxy and/or methoxy substituted isoflavone 1 with four 
groups: isoflavan-4-ols 3, isoflav-3-enes 5, isoflavans 4 and -methyldeoxybenzoins 
(1,2-diarylpropan-1-ones) 7, which are all reduced metabolites of food derived 
isoflavones in mammals (Fig. 1). Related isoflavan-4-ones 2 are briefly discussed. 
Results of an extensive survey of the literature concerning the synthesis of 
polyhydroxy- or methoxysubstituted  isoflavonoids and especially asymmetric 
approaches are discussed. The motivation for this work came from the lack of 
expedient synthesis methods to prepare polyphenolic isoflavonoids. Particularly, the 
need for enantiopure or diastereopure reference compounds for use in clinical studies 
and biological activity studies gave reason to study isoflavonoid chemistry further.  
 
Isoflavones 1 (3-phenyl-4H-1-benzopyran-4-ones or 3-phenylchroman-4-ones) are the 
biggest subgroup in the isoflavonoid family in plants. Isoflavones occur mainly in the 
Leguminosae family, soy being the most important plant in human nutrition.1 
 
 
 
Fig. 1. Isoflavonoid 1-13 and flavone 14 skeletons and numbering of rings A, B and C 
according to Dewick.1 

In recent times, an enormous increase has been observed regarding the study of 
human metabolism of food derived isoflavones into reduced isoflavonoid 
substructures such as isoflavan 4 or isoflav-3-ene 5. Isoflavonoid clinical studies have 
focused on isoflavan equol 15 in particular, which is a reduced metabolite of one of 
the most abundant natural isoflavones, daidzein 16. For example in 2010, the biannual 
international symposium on the role of soy in preventing and treating chronic disease 
dedicated one day just for equol research.2 One of the topics was efficacy and safety 
of the natural S-equol supplementation for menopausal healthcare. This clearly 
demonstrates a trend in the study of isoflavone metabolism associated with the claims 
that isoflavones are beneficial to health. The first reduced isoflavone metabolite 
identified in human urine after consumption of an isoflavone rich diet is equol:3,4 this 
is consistent with equol being studied in the biggest number of publications among 
the reduced metabolites (Fig. 2). 
Fig. 2 Frequency of publications concerning equol and isoflavan or isoflavene in 
general from 1990 to 2010 searched in SciFinder. 
During the 21st century the number of patent applications concerning the potential 
daidzein metabolite dehydroequol 17 (7,4’-dihydroxyisoflav-3-ene)5-19 together with 
equol 1520  have increased dramatically. Their value and interest as patentable 
compounds, in particular, has increased due to their use as therapeutic agents in 
different diseases, as food supplements to improve human health, or as ingredients in 
cosmetic products against skin aging.19,21 Rising numbers of patent applications 
concerning either their preparation methods or their use as therapeutic agents 
demonstrate the rising interest of pharmaceutical and health oriented companies 
towards these reduced metabolites of natural isoflavones. 




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1.1. Isoflavonoid sources in nutrition, mammalian metabolism and biological 
activities  
 
Isoflavones are the biggest subgroup of isoflavonoids, which are secondary 
metabolites formed in plants to act as phytoalexins. They are formed biosynthetically 
by the  phenylpropanoid pathway from flavonoids by isoflavone synthase (IFS).22 
These plant defensive compounds have raised special attention in medicinal and 
biological disciplines due to their various physiological effects also in mammals. For 
example, the effects of dietary flavonoids and isoflavonoids on xenobiotic and 
carcinogen metabolism have been under study.23  
 
Isoflavonoid sources in human and other mammal nutrition 
 
 
Soy beans contain the phytoestrogenic isoflavones daidzein 16 and genistein 18.1 Soy 
is the most important isoflavone source in human nutrition. The typical isoflavone 
intake in Western cultures is less than 1 mg/d, whilst in Asian countries it is as high as 
20-50 mg/d due to high soy consumption.25 
 
Red clover (Trifolium pratens), which is used in organic farming as cow feed in 
Finland, also incorporates isoflavones abundantly, mostly formononetin 19 and 
biochanin A 20, but also their 4’-O-demethylated forms daidzein and genistein. Red 
clover isoflavones and their reduced metabolites are potential components also in 
human nutrition for example, if organic cow milk is consumed.26 Red clover extracts 
are also used as food supplements in human nutrition due to anticipated  beneficial 
effects of isoflavones to human health. 
 
In plants, isoflavones occur mostly as glycosides having a sugar moiety. For example 
the precursor of daidzein, daidzin 21 (daidzein-7-O--glycoside) has a glycoside 
group connected to its 7-O- position. 
 
Isoflavonoid metabolism studies 
 
The known isoflavone metabolite equol 15 (7,4’-dihydroxyisoflavan) was first 
identified in the urine of pregnant mares and was found to be estrogenic.27 Equol itself 
does not occur in any plant. It has been isolated as a mammalian metabolite of 
isoflavones present in food. Isoflavone metabolism studies received more attention in 
the 1940’s, when subterranean clover grazing ovines were found to suffer from an 
infertility syndrome in Western Australia: from whence feed derived isoflavonoids 
were implied as a cause for hormonal disorders.28 
 
The red clover isoflavones formononetin 19 and biochanin A 20 are first converted 
into the main soy isoflavones daidzein 16 and genistein 18 by mammalian gut 
microflora and further metabolised to various mostly unknown reduced structures. 
There seem to be  notable differences between species and even individuals in their 
ability to metabolise food isoflavones. According to a study by our group and our 
collaborators, only 30 - 50% of the people studied were able to convert daidzein to 
equol 15 and 80-90% to ODMA 22.VI Gut microflora have an important role in 
isoflavone metabolism. For example germ free rats did not convert soy isoflavones to 
 
equol,2 and newly born babies are not able to produce equol after soy milk 
consumption due to the lack of intestinal bacteria.30,31 Specific enzymes involved in 
the metabolism of dietary isoflavones, including daidzein, in man are currently 
unknown.32  
 
In man, the metabolic pathways discovered thus far produce reduced metabolic 
structures such as equol 15  and O-DMA 22.33-35  Some minor hydroxylation36-38  of 
isoflavones 1  and/or their reduced derivatives has also been reported,39,40  however the 
concentrations of these oxidised forms are only fractional compared to the reduced 
metabolites.  
Isoflavone metabolism in man has only been studied to some extent thus far; 
predominantly in vitro studies, and some qualitative GC-MS analysis have been 
reported.41-43  Our group identified an isomer of equol, 3’,7-dihydroxyisoflavan 23 
from human urine (Fig. 3).44 The same compound has also been discovered from 
cow’s milk.44  Our group also identified 6´-OH-ODMA 24 as the second human 
metabolic -methyldeoxybenzoin derived from genistein.45  
Isoflavone metabolism studies have also suffered from incorrect interpretations of 
GC-MS results due to the lack of authentic reference compounds. For example, one 
proposed daidzein metabolite from human urine was claimed to be 2,3-dehydro-O-
DMA 25 and another the enol tautomer 27 of dihydrodaidzein 26 (Fig. 3).46,47 
However,  our group has shown that these compounds are just artefacts arising in the 
silylation of dihydrodaidzein during sample preparation and they are thus not true 
metabolites of daidzein.45  
 
 
 
Fig. 3. Isoflavonoids discussed in the metabolism section. 
 
The proposed main metabolic pathway for the soy isoflavone daidzin 21 in man is 
presented in Scheme 1. Biological activities or absolute configurations of most of the 
chiral metabolites have not yet been clarified in great detail in any species. Our group 
has identified  the daidzein metabolite 7,4’-dihydroxyisoflavan-4-ol 28 to be cis-
isomer, by applying the synthetic diastereopure reference compound.45  In contrast to 
this result, Kim and Han and coworkers claimed that this natural metabolite is the 
trans-isomer according to their semi-empirical CD studies with theoretical simulation 
of the chiroptical transitions.48-50 In the two later publications they reported that their 
initial absolute configurational determinations by used spectroscopic methods (CD, 
ECD) were not reliable (discussed in more detail in section 1.2.1). Also reported 
chemical structures were incorrectly drawn. The absolute configuration of the 
mammalian metabolite equol 15 was not determined before this thesis work due to 
lack of enantiopure reference compound. 
 
 
 
Scheme 1. The proposed main catabolic pathways of natural soy isoflavone daidzin 
based on the urinary isoflavonoid metabolites found in human urine45,51 Dotted arrows 
indicate only tentative identification.  
 
 
Biological effects of isoflavonoids 
 
The most abundant soy isoflavones, daidzein 16 and genistein 18,  are able to bind to 
estrogen receptors (ER) in mammals due to their structural similarity to natural 
hormone estradiol. 52 Isoflavone metabolites, such as the isoflavan equol 15, bind with 
even  higher affinity and thus have stronger biological effects than the parent 
 
compound daidzein 16.53 Equol is also a potent inhibitor of the Na-K-Cl cotransport 
system.54 Our group recently participated in a study of equol’s ligand binding capacity 
for  estrogen-related receptor  (ERR ).55 Equol 15 was demonstrated to act as an 
ERR agonist and is therefore capable of enhancing the growth inhibitory effect of 
ERR on the prostate cancer PC-3 cells. 
 
Chiral equol is capable of binding to both estrogen receptors alpha and beta.56 The S 
and R enantiomers of equol (29, 30 respectively), obtained by chiral HPLC of the 
racemic mixture, have been shown to have different binding affinities to the estrogen 
receptors  and ; the R enantiomer preferring the ER and the S enantiomer 
preferring the ER. The S-enantiomer of equol 29 is also a potent antagonist for 
dihydrotestosterone, a growth stimulant for the prostate gland.57 
According to in vitro studies, isoflavonoids may also prevent osteoporosis.58-60  Our 
group studied the antitumor activities of the reduced metabolites of daidzein trans- 
and cis- tetrahydrodaidzein 31 and 28 in an in vitro study. They were shown to be 
comparable to genistein 18 against human prostate cancer cells.61 The same 
compounds are also known potent antioxidants.62  
 
The first identified human metabolic  methyldeoxybenzoin (1,2-diarylpropan-1-
one), the triphenolic O-DMA 22, has shown equal binding activity to that of  
endogenous estradiol (E2) binding to estrogen receptor  in an in vitro experiment.63 In 
contrast, isoflavones genistein 18 and daidzein 16 showed weaker binding activity 
than O-DMA 22. 
 
1.2. Synthesis of isoflavonoid metabolites 
 
Prior to this work, the absolute configurations of natural chiral isoflavonoids in man 
and other mammals were not determined using authentic chiral reference compounds. 
Synthetic isoflavonoids related to this thesis were also needed in our collaborative 
studies to measure their biological activities.V A thorough review of the literature 
suggested the lack of suitable synthesis methods to prepare polyphenolic 
isoflavonoids in general and especially the lack of asymmetric approaches was clear. 
 
 
 
 
1.2.1 Synthesis of Isoflavan-4-ols 
   
To date, there are no reports about the synthesis of the single enantiomers of 
isoflavan-4-ols 3. In general, only unsubstituted or alkoxysubstituted isoflavone 1a-b 
reductions by nucleophilic hydrides such as NaBH4 to prepare mixtures of 
diastereomeric isoflavan-4-ols (cis- and trans-32 a-b) were described prior to 
commencement of this work (Scheme 2.). 64-66 
 
 
 
 
Scheme 2. Reduction of methoxy- or unsubstituted isoflavones with sodium 
borohydride. 
 
The reduction of nonphenolic isoflavan-4-ones 2 by LiBH4, NaBH4, L-Selectride or 
Li(t-BuO)3AlH has also been used to produce mixtures of trans- and cis-isoflavan-4-
ol enantiomer pairs cis-32, trans-32 (cis/trans ratio 4:5 – 4:3). 67,68 
 
Unsubstituted or methoxysubstituted cis-isoflavan-4-ols cis-32 a-b have been 
produced from isoflavan-4-ones 2 by the use of large excess (80 eq) of electrophilic 
hydrides (borane-THF, BTED).68 Furthermore, a synthesis of methoxy or  
unsubstituted trans-isoflavan-4-ols 33a-b by hydroboration of the corresponding 3-
aryl-4-hydroxycoumarins 34a-b in 42-54% yields was performed (Scheme 3).  
 
 
 
Scheme 3. Trans-isoflavan-4-ols by a hydroboration of 3-phenyl-4-
hydroxycoumarins. 68 
 
The first papers describing the synthesis of diastereomeric mixtures of trans- or cis-
isoflavan-4-ols 32 had no NMR information and there was no reliable data available 
for structural assignments.  
An approach to synthesise the 2-aryl substituted isoflavan-4-ol analogue 35 was 
published by Venkati and Krupadanam69 who reported the synthesis of 2,3-trans-3,4-
trans-2-aryl-3- arylchroman-4-ol 35 starting with the Knoevenagel reaction of 
aldehyde 36 and 7-O-methoxydeoxybenzoin 37 (Scheme 4) with an unknown total 
yield.  
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 	
 
Scheme 4. Synthesis of 2-aryl substituted analogue of isoflavan-4-ol 35 starting from 
p-methylbenzaldehyde 36 and 2’-hydroxy-4’-O-methyldeoxybenzoin 37.69  
 
There is an isolated study about the chiral HPLC separation of a racemic mixture of 
unsubstituted isoflavan-4-ol stereoisomers:48 the semi-empirical analysis about the 
absolute configurations by CD and optical rotation of the isoflavan-4-ol stereoisomers 
is also reported: however, these results were reported to be unreliable more recently 
due to the spectroscopic methods used.49,50 To correct the unreliable configurational 
results, ECD spectroscopy with theoretical TD-DFT computations were used. The 
observed experimental ECD spectra resulted in a poor simulation, and thus 
inconclusive absolute conﬁgurational assignments of isoﬂavan-4-ol stereoisomers 
were again obtained. The correct absolute configurations of the four stereoisomers 
were determined by yet another method. DFT- assisted VCD spectroscopic analyses 
confirmed the absolute configurations of the isoflavan-4-ols 3. The absolute 
configurations of the isoflavan-4-ols were further confirmed by a modified Mosher 
method, yielding results opposite to their initial assignments. However, reported 
chemical structures were incorrectly drawn and thus this data remains unclear. 
 
Without synthetic enantiopure reference compounds, the elucidation of the correct 
stereochemistry of the natural metabolite is thus complicated and time consuming 
requiring various spectroscopic methods and theoretical calculations. Only single 
crystal X-ray crystallography will give absolute configuration most reliably, if good 
quality crystals are available.  
 
 
 
 
 
 
 
 
 

1.2.2 Synthesis of isoflav-3-enes and isoflav-2-enes 
 
Synthesis of isoflav-3-enes 5 are only rarely described in the chemical literature. Even 
fewer papers describe the synthesis of isoflav-2-enes 6. The promising anticancer70 
isoflavonoid dehydroequol 17 (other names for 17 according to SciFinder are 4’,7-
dihydroxyisoflav-3-ene, 3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol, phenoxodiol, 
haginin E or idronoxil)  has been isolated from the plant Lezpedeza homoloba.71 It has 
been suggested as a human metabolite of the isoflavone daidzein, and has raised 
interest also as an antioxidative71 and antiinflammatory72 agent. Dehydroequol and 
related structures have also been suggested as potent synthetic estrogens or 
antiestrogens.73-77 Dehydroequol 17 was found to prevent immune suppression induced 
by UV radiation and thus may have a future role as sun-protective cosmetic 
ingredient. It is also suggested to be  a novel cardioprotective therapeutic together 
with other tested isoflavonoids dihydrodaidzein 26, equol 15, cis- and trans-
tetrahydrodaidzein 28, 31.78 Detailed studies on the dehydroequol 17 and other 
phenolic isoflav-3-enes have been made difficult by the lack of synthesis methods 
reported in the literature. Just recently natural phytoisoflavonoid, 2’,3’-
dimethoxydehydroequol (Haginin A) 38 was isolated from the branch of Lespedeza 
cyrtobotrya.79 Haginin A exhibits a strong hypopigmentary effect in Melan-A cells 
and significantly inhibits melanin synthesis according to Kim et al.79  
 
 
 
There are only a few papers describing the synthesis of this class of compounds, 
which have low yields, are unselective and contain no hydroxysubstitution.   
 
The first approach to synthesise nonphenolic isoflav-3-enes 5 was the acid-catalysed 
dehydration of isoflavan-4-ols 3 prepared by hydride reductions of isoflavone 1 or 
isoflavan-4-one 2.80-82 The intermediate isoflavan-4-ols were usually not isolated but 
were dehydrated directly to the isoflav-3-enes. Also one patent application about the 
multistep synthesis of polyphenolic isoflav-3-enes by dehydration of isoflavan-4-ols 
in unspecified total yield has been published.83 In our experience this reduction 
dehydration sequence does not work for phenolic compounds due to the mixtures of 
products obtained and target isoflav-3-enes are formed only as minor products if at 
all.VII  
 
The synthesis of 1:1 mixtures of isoflav-2-enes 39 and isoflav-3-enes 40 in 3-10% 
yields from isoflavylium salts 41 has been reported (Scheme 5),84 whilst other 
publications describe nonphenolic isoflavylium salts as intermediates in the synthesis 
of isoflav-3-enes and /or isoflav-2-enes.85-87 
  
 
 
 
Scheme 5. Reduction of isoflavylium salt 41 with sodium cyanoborohydride to the 
1:1 mixture of corresponding isoflav-2-ene or isoflav-3-ene in 3-10% yields.84  
 
There are also isolated papers describing the syntheses of unsubstituted or alkoxy or 
halosubstituted isoflav-3-enes and /or isoflav-2-enes. One method involves the 
reduction of isoflavones by the Clemmensen reaction (Scheme 6).88 
 
 
 
 
Scheme 6. Synthesis of isoflavenes by the Clemmensen reduction, in which 4-OH 
products are not intermediates.88 
 
A low-yielding non-reductive method to produce isoflav-2-enes 42 has also been 
reported, involving a palladium-catalysed tandem cyclisation-hydride capture process 
starting from bromobenzoacetophenone 44 and iodophenol derivative.89 The multistep 
route produces protected isoflav-2-ene 42 together with benzofuran 43 unselectively 
(Scheme 7). 
 
 
 
 
     
 
 
  
 
Scheme 7. Preparation of isoflav-2-enes 42 together with 3-aryl-2,3-dihydrobenzo-
furans 43.89  
 
Another non-reductive route to produce the monobenzyloxy isoflav-3-ene 45 was 
introduced by Simas et al.90 Production of 3,4-chromene 46 after conjugate addition 
of phenyl lithium and desulfonation leads to isoflavan 47, isoflav-3-ene 45  or 
isoflavan-4-one 48  (Scheme 8). 
 
 
 
 
 
 
Scheme 8. Synthesis of isoflav-3-ene 45, isoflavan 47 and isoflavan-4-one 48 
structures through 4-chromenesulphone.90  
 
Only recently, Li et al. (2009) published the total synthesis of dehydroequol 17 
(Haginin E) and equol 15 starting from resorcinol 49 via the protected isoflavene 
intermediate 50 (Scheme 9).91 This multistep approach seemed complicated and time 
consuming. It contains a two step formylation of resorcinol 49 to corresponding 
benzaldehyde 51, which was further protected by monobenzylation to 4-
benzyloxysalicylaldehyde 52. Then a Wittig reaction, O-alkylation, and another 
Wittig reaction produces the diene 53, transformed into an intermediate isoflav-3-ene 
50 by a ring-closing metathesis using Grubbs’ catalyst (2nd generation). Finally, after 
deprotection with BCl3 under varying conditions the target isoflav-3-enes, Haginin E 
17 or O-methyl derivative 54, were derived to give approximately 26% yields. Also 
4’-O-methylequol 55 or equol 17 could be obtained from the intermediate isoflav-3-
ene 50 by Pd(OH)2 in EtOH and cyclohexene reflux. Alternatively, the corresponding 
7-O-benzyl-4’-O-methylisoflavan-4-ol 56 could be obtained in moderate 20% total 
yield by BH3-SMe2 in THF followed by treatment with water, 10% NaOH and 37% 
hydrogen peroxide. The protected isoflavan-4-ol 56 was used as starting material to 
prepare the protected isoflavone 57 and after demethylation or debenzylation gave 
isoflavones daidzein 16 and formononetin 19. 
 
The total synthesis required several steps and chromatographic purifications, the first 
one already in the preparation of the starting material 4-benzyloxysalicylaldehyde 52. 
The overall yield of dehydroequol 17 was 26% and for daidzein 16 less than 15%. 
 
 
Scheme 9. Synthesis of Haginin E 17, equol 15 and other isoflavonoids starting from 
resorcinol (Li et al.).91  
 
 
 
 
Gupta and Ray presented a synthesis of dehydroequol 17 through a Friedel-Crafts (F-
C) acylation reaction of 3-methoxyphenol 59 and 4-hydroxyphenylacetic acid 60 
(Scheme 10).92 By the F-C reaction they obtained a mixture of two deoxybenzoins, 
4”-O-Et substituted 62 and 4”-OH substituted 63. After chromatographic separation, 
the 4”-ethoxydeoxybenzoin 62 was reacted by cross aldol condensation with 
paraformaldehyde in an aqueous solution of sodium hydroxide to yield the 
corresponding isoflavan-4-one 61. The reduction of the carbonyl group by NaBH4 in 
methanol gave the isoflavan-4-ol 64, which was dehydrated into protected 
dehydroequol 65 by hydrogen chloride (HCl) in ethanol and then underwent 
deprotection by pyridinium hydrochloride to give dehydroequol 17 in a total yield of 
27%. The route contained two chromatographic purifications of the intermediates and 
a third for the final product purification, thus was not a very efficient procedure. 
Furthermore, the use of ethoxylated deoxybenzoin 62 instead of free phenolic 63 was 
quite unexpected. The ethoxylated deoxybenzoin 62 is a side product formed from 
decomposed boron trifluoride etherate (BF3OEt2) if freshly distilled BF3-etherate is 
not used and is not normally formed.93  
      
Scheme 10. Synthesis of dehydroequol 17  starting by Friedel-Crafts acylation of 
protected resorcinol 59.92 
 
Recently, Erhardt and coworkers have published two articles and one patent 
application regarding the synthesis of isoflav-3-enes 66, 67 as key intermediates for 
the first total synthesis of racemic and natural enantiopure pterocarpans, (-)-glyceollin 
68 and its derivatives.94-96  They used a Wittig reaction to produce the isoflav-3-ene 
substructures with appropriate MOM/Bn/TBDMS-protected substitution patterns with 
a yield of less than 12% overall as shown in Scheme 11. 
 
 
 
Scheme 11. Synthetic route used to prepare protected DHE 67 as starting material for 
racemic and natural glyceollin 68 and derivatives.94-96 
  
1.2.2.1 2-O-Substituted or 2-N-substituted isoflav-3-enes 
 
There are also some examples of the synthesis of 2-O- or 2-N-substituted isoflav-3-
ene analogues, which are not true isoflavonoid derivatives. The preparation of isoflav-
3-ene analogues with 2-O-substitution 70, 71 has been performed by reduction of 3-
arylcoumarins 69 (Scheme 12).77,80,97-99 Synthesis of 2-OH-isoflav-3-ene 72 from 
protected salicylaldehyde 73 and arylglycidate salt 74 has also been reported (Scheme 
13).86 
 
 
 
 
Scheme 12.  Synthesis of a 2-O-substituted isoflav-3-ene analogue 71 starting from 
corresponding 3-arylcoumarin 69.77 
 
 
 
 
Scheme 13. Synthesis of a 2-OH-isoflav-3-ene 72 from protected salicylaldehyde 73 
and arylglycidate salt 74.86 
 
 
Varma and coworkers reported a method to produce nonphenolic 2-
morpholinoisoflav-3-enes 75 with no other substitution or monomethoxy substitution 
via the condensation of N-styrylamines 76 with ortho-hydroxyarylaldehydes 77 to 
give 46-55% yields (Scheme 14).100-102  Later, they prepared other 2-N-substituted 
(morpholino, piperidino or pyrrolidino) derivatives of isoflav-3-enes under solvent 
free conditions using microwave irradiation in the presence of ammonium acetate as a 
catalyst to give 73-80% yields.103 
 
Scheme 14. A solvent-free preparation of 2-morpholino-substituted isoflav-3-enes 
75a and 75b using microwave irradiation (Varma and !"#).103 
 
The formation of the 2-N-isoflav-3-ene derivatives 75 through the dehydration of the 
intermediate 2-N-isoflavan-4-ols was explained by the mechanism shown in Scheme 
15.  
 
Scheme 15. Proposed mechanism for the formation of 2-N-isoflav-3-ene derivatives 
75.103 
 
 
1.2.3 Synthesis of isoflavans    
       
The preparations of isoflavans 4 reported in the literature are mainly based on the 
catalytic hydrogenation of nonphenolic isoflavones 1. Hydrogenation reactions have 
been achieved by palladium catalysis on a variety of  supporting materials such as 
charcoal, calcium carbonate (CaCO3), aluminium oxide (AlO2) or barium sulfate  
(BaSO4) in different reaction media with varying results. The yields and product ratios 
are dependent on the concentration, pH, solvent, protection groups  and the reducing 
reagent used. Hydrogenation of isoflavones 1 is reported to give mixtures of 
isoflavans 4, isoflavan-4-ones 2, isoflavan-4-ols 3, -methyldeoxybenzoins 7, 
deoxybenzoins 78, pterocarpans 8, 3-cyclohexyl-3,4-dihydro-2H-1-benzopyrans 79, 
3-phenyloctahydro-2H-chromenes 80, isoflav-3-enes 5 or isoflav-2-en-4-ols 81 (Fig. 
1, Fig. 4).67,80,104,106-113           
 
 	
 
 
Fig. 4. Structures of the reported hydrogenation products of isoflavones discussed in 
section 1.2.3. 
 
Additionally, the isolated total syntheses of racemic isoflavans have been reported, 
but  mostly in quite low yields with time consuming procedures.  
 
At the time of this thesis work, no method to prepare enantiopure polyphenolic 
isaflavans (such as (S)-equol 29 or (R)-equol 30) had been reported in the literature.  
Even to date, only two papers and one patent application describing the asymmetric 
multistep total syntheses of chiral phenolic isoflavans have been published (Heemstra 
et al. 2006 , Takashima et al. 2010,  Setchell and Sorokin 2010; in more detail section 
1.2.3.3).114-116 
 
 
 
1.2.3.1 Catalytic hydrogenation of isoflavones 
The most commonly used hydrogenation catalyst for isoflavones is palladium on 
charcoal (5 or 10% w/w). Different solvents  and pH conditions have been used to try 
to optimise  the reactions or improve the selectivity. Table 1 provides a summary of 
variable results of the Pd/C catalysed hydrogenation reactions of a number of 
isoflavones under different conditions collected from the literature.  
 
As can be seen in Table 1, results vary from one study to another depending on the 
Pd:isoflavone ratio, solvent, hydrogen consumption, reaction temperature, catalyst 
type or supplier used. Szabo et al. (1973, 1976) studied the effects of pH, different 
solvents and the amount of H2 consumed.110,111 Four different reduced structures were 
claimed to be produced in different reaction media. Chang et al. (1995) also reported 
product variability derived from the different solvents used.104 In previous experiments 
performed in our laboratory, no other products than isoflavans 4 were produced, 
regardless of which solvent was used.117 
The identification of the products have also been uncertain in several cases. Chang et 
al. reported that the hydrogenation of daidzein 16 over 5% Pd/BaSO4 in EtOH 
produced the corresponding isoflavan-4-one (dihydrodaidzein) 26 as the major 
product.104 The identification of their synthetic product was said to be based on the 
comparison of 1H NMR shifts with published values not given in the paper. In one 
report, Pd on aluminium oxide and on calcium carbonate were claimed to have low 
selectivities and activities, but no product data was given.111 One report claimed 
isoflavan-4-ones 2 as reduction products with palladium on CaCO3 in ethanol, but 
identification of the compounds was based only on MS.118 A more recent paper 
(2009)119 reported a variety of products to be formed from the reduction of daidzein 
with different Pd/C catalyst types used in AcOH-EtOH (1:9 to 1:99). The solvent ratio 
was reported to have a significant effect on the reaction rate and products formed. A 
 

new isoflavonoid structure was also claimed to be formed, namely 7,4’-
dihydroxyisoflav-2-en-4-ol 82 from the reduction of the corresponding isoflavone 
daidzein 16, but no spectral data to confirm the structure or other physical properties 
were given. 
 
In general, isoflav-2-en-4-ols 81 have only rarely been mentioned in the chemical 
literature and no reliable spectral data have been reported so far.120 The first mention 
was made by Thakar et al.121 when they claimed to have prepared unsubstituted 
isoflav-2-en-4-ol 81 in 75% yield by a hydride reduction with NaBH4 of the 
corresponding isoflavone 1 in ethanol, whereas isoflavan-4-ol 3 (88%) was obtained 
in diglyme. Product characterisation relied on the elemental analysis (C15H12O2) only. 
It should be kept in mind that the same elemental composition fits also to isoflavan-4-
ones 2 (enol tautomer isoflav-3-en-4-ols 83), which is also a potential hydride 
reduction product of isoflavones 1 (Fig. 1).122,I Only recently (2010), a patent 
application was published concerning a selective reduction of isoflavone 4-keto group 
to 4-hydroxy, without the reduction of the 2,3-double bond.123 This may have occured 
via enzymatic or hydride reduction, various hydride reduction reagents were 
suggested; however no identification data such as spectral or crystallographic data or 
melting points were given for isoflav-2-en-4-ols 81 and thus this data is not entirely 
reliable. 
 
Fig. 5. The elemental composition of the hypothetical isoflavonoid metabolite 81 is 
shared with the isoflavan-4-ones 2. 
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1.2.3.2 Multistep total syntheses 
 
For the preparation of isoflavans with unsaturated substituents, other methods than the 
reduction of isoflavones have to be used. For example, prenyl substituted isoflavan 5-
O-methyllicoricidin 84 (Scheme 16)135 was prepared by a complex 15-step route 
containing Wittig olefination and allylic oxidation by selenium dioxide, two 
Mitsunobu reactions, Claisen rearrangement, selective hydroboration and finally 
nuclear alkylation of the second intramolecular Mitsunobu reaction product 91, which 
had produced the isoflavan moiety. A major drawback in the route was the need of 
chromatographic flash purification of the acid sensitive Claisen rearrangement 
intermediate 88. The Claisen rearrangement also yielded 2-methyl-2-phenyl-2,3-
dihydrobenzofuran 89 as reaction byproduct. The overall yield was less than 5 %.  
 
 
Scheme 16. Total synthesis of 5-O-methyllicoricidin 84.135 
 
Methoxy-, nitro- and unsubstituted isoflavans, such as 100, have been prepared in 16-
29% yields by rhodium-catalysed intramolecular nucleophilic substitution of the 
corresponding 3-(2-fluorophenyl)propan-1-ol 99 (Scheme 17).136 The overall yields of 
isoflavans were less than 2%.  
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Scheme 17. Synthesis of isoflavan 100 by rhodium-catalysed intramolecular 
nucleophilic substitution of the corresponding 3-(2-fluorophenyl)propan-1-ol 99.136 
* Rhodium(2+), (6-benzene[1,2,3,4,5-]-1-ethyl-2,3,4,5-tetramethyl)-2,4-
cyclopentadien-1-yl, hexafluorophosphate(1-) (1:2) 
 
 
Liepa86 and Deschamps-Vallet et al.87 have synthesised isoflavans 101 from 
isoflavylium salts 102 through coumarins 103 and isoflav-3-enes 104 in 3 steps 
providing a 30-70% yield of racemic isoflavans 101 (Scheme 18). The isoflavylium 
salts 102 were initially synthesised from phenols and arylmalondialdehydes. 
  
 
Scheme 18. Preparation of isoflavans 101 from isoflavylium cations 102.86,87 
 
 
Usse et al. prepared unsubstituted 105 or monomethoxyisoflavans 106 in 3 steps 
starting from chromanone 107, which was converted to a triflate 108 and coupled with 
phenylboronic acid and finally hydrogenated with Pd/C in MeOH/CH2Cl2 to yield 
isoflavans 105-106 in unspecified total yields (Scheme 19).137 
 
 
Scheme 19. Isoflavans 105-106 by  Suzuki coupling of triflates 108 and phenyl 
boronic acids starting from chromanones 107 by Usse et al.137  
 
Isoflavans 4 have also been prepared via isoflav-3-enes 5138-141  with multistep 
reactions and moderate yields by catalytic hydrogenations. Conti et al.139 and Burali et 
al.140 prepared isoflavans 109 in four steps starting from ortho-hydroxybenzyl 
alcohols 110 and -bromoacetophenones 111 to yield 1-aryl-2-(o-
hydroxymethyl)phenoxyethanones 112, which were converted into the corresponding 
triphenylphosphonium bromides 113. After the Wittig intramolecular cyclisation of 
triphenylphosphonium bromides 113 to isoflav-3-enes 114, Pd/C-catalysed 
hydrogenations gave isoflavans 109 as shown in Scheme 20. The reaction was not 
useful for chloro- or bromosubstituted derivatives, because partial dehalogenation 
occurred producing a product mixture. 
 
 
 
Scheme 20. Synthesis of isoflavans 109a-b through the Wittig intramolecular 
cyclisation. Chloro- or bromo- substitution lead to partial dehalogenation in the last 
step and gave lower yields due to product mixtures.140 
 
 
 
Recently, Gharpure et al. presented a multistep ortho-quinone methide 117 based 
approach to racemic mixtures of natural isoflavans equol 15, 3’-hydroxyequol 115 
and vestitol 116 (Scheme 21).142 O-Methyl- or O-benzyl protected o-quinone methides 
117 and aryl-substituted enol ethers 118 reacted in a Diels-Alder reaction followed by 
reductive cleavage of the methoxy acetal group of 119 using a Lewis acid and 
trialkylsilane. Then demethylation by pyridinium hydrochloride or debenzylation of 
120 by H2/10% Pd/C in EtOAc gave hydroxyisoflavans in moderate yields.  
 
  
 
Scheme 21. Synthesis of racemic isoflavans 15, 115, 116 by an ortho-quinone 
methide 117 based approach.142  
 
Gupta and Ray presented a synthesis of rac-equol 15 through the Friedel-Crafts 
acylation reaction of 3-methoxyphenol 121  with 4-hydroxyphenylacetic acid 122. By 
modifying the reaction dehydroequol 17 could also be obtained as described earlier in 
 
the previous section (Scheme 10).92 The formed isoflavan-4-one 123 was reduced to 
the corresponding isoflavan 124 by Pd/C hydrogenation, further converted to equol 15 
by dealkylation with pyridinium hydrochloride in a 22% overall yield as shown in 
Scheme 22. The route contained two chromatographic purifications of intermediates. 
The final product also required chromatographic purification, thus causing low yields 
and numerous tedious steps.  
 
Scheme 22. Synthesis of racemic equol 15 starting by a Friedel-Crafts acylation of the 
protected resorcinol 121.92 
 
 
1.2.3.3 Synthesis of enantiopure isoflavans 
 
There are only a few reports in the literature regarding the synthesis of enantiopure 
isoflavans. Natural isolated enantiopure pterocarpans 8 have been used to prepare 
chiral isoflavans 2 by Pd-catalysed hydrogenations to give approximately 70% 
yields144 or unspecified yields.144 This method however required a tedious 
chromatographic separation of natural starting materials at the beginning.  
 
Versteeg et al.145,146 prepared non-phenolic isoflavans 128 via the -alkylation of  
phenylacetate derivatives 129. The total yield starting from the synthesis of suitable 
benzyl bromide  130 was 15-21%, however this decreased when a more highly 
substituted benzyl bromide was used as a starting material. Various amounts of 
unwanted isomeric compounds, 2-benzyldihydrobenzo[b]furans 131, were formed as 
byproducts in the last cyclisation reaction.  
 
Modification of the method by using a chiral auxiliary (imidazolidin-2-ones 132, 
133), gave the enantiopure methoxy substituted isoflavan 128.147,148 The reaction 
started by stereoselective -benzylation of phenylacetic acid derivatives 129149-153    
(diastereomeric excess, de > 95%) and in the last step a Mitsunobu reaction was used 
to close the heterocyclic ring C. After reductive removal of the chiral auxiliary and 
cyclization, methoxysubstituted chiral isoflavan 128 was prepared in a total of 6-7 
steps in a 35% yield  (enantiomeric excess, ee > 96%) in a total of 6-7 steps (Scheme 
23). However, the cleavage of the methoxy substitution was not published at the time, 
and was not even attempted for the production of chiral hydroxy substituted natural 
isoflavan (S)-equol 29. 
 
 
Scheme 23. First asymmetric route to methoxysubstituted isoflavan 128.147,148 
 
No asymmetric synthesis route to (S)-equol 29 or other free phenolic isoflavans were 
available at the time of this work. At the same time as we filed our own patent 
applicationIV about the asymmetric hydrogenation of dehydroequol derivative to 
prepare (S)-equol 29 and (R)-equol 30 (Scheme 46, section 3.4.2 Results and 
discussion), Setchell and Sorokin had filed their patent application (2005).116 Their 
approach was longer than ours, but they also used asymmetric hydrogenation of 
chromenes as a key step to prepare enantiopure isoflavan (S)-equol 29 (Scheme 24). 
The overall yield in their  6 step route to (S)-equol was 38.9%. 
 
 
Scheme 24. Setchell’s and Sorokin’s asymmetric hydrogenation of the protected 
chromene 137 to prepare S-equol 29.116  
 
 
They prepared the key intermediate isoflav-3-ene 137 by previously known reductive 
sequences. Protected isoflavone 134 was reduced to isoflavan-4-one 135, which was 
reduced to the corresponding protected isoflavan-4-ol 136 and further dehydrated to 
isoflav-3-ene 137 by methanesulfonic anhydride and triethyl amine in THF at room 
temperature. Shortcomings of the method of preparing 29 were the several steps, and 
the need to use energy consuming cryo chemistry and chromatographic purifications 
with toxic hexane as eluent in several steps. It should be mentioned that the melting 
point of their synthetic claimed enantiopure (enantiomeric excess, ee 100%) (S)-equol 
was considerably lower, only 162 oC, compared to previously reported natural isolated 
enantiopure equol (191 – 193 oC).154 
 
After this thesis work and filing the patent applications, the second asymmetric 
synthesis of (S)-equol 29 by a total synthesis was reported (Scheme 25).114 The 
stereocenter was formed by Evans alkylation using a chiral auxiliary 138 ((S)-4-
benzyloxazolidin-2-one). The key step to create the chiral center by Evans alkylation 
was very similar compared to the previously presented Versteeg et al. approach 
described in scheme 23. Intramolecular Buchwald etherification formed the chroman 
ring to give the isoflavan moiety 141, whereas the Mitsunobu reaction was used in 
Versteeg et al.’s approach. The method was only used for the enantiopure equol 29/30 
production and no other chiral isoflavans were reported. Demethylation of protected 
isoflavan 141 was actually the only major difference in this approach compared to the 
Versteeg et al. procedure as they produced the natural phenolic chiral isoflavans 29 
and 30. 
 
 	
 
Scheme 25. Total synthesis of enantiopure (S)-equol 29 by an asymmetric Evans 
alkylation to create the chiral center in 139.114  
 
 
The most recent asymmetric synthesis by Takashima et al. (2010) produced (S)-equol 
29 by a 15 step procedure.115,155 This approach also used allylic substitution as a key 
step to produce chirality (Scheme 26).  
 $
 
Scheme 26. Enantioselective total synthesis of (S)-equol 29 by allylic substitution as 
the key step that gives a yield of approximately 24%.115,155 
 
The method was only applicable to prepare chiral equol 29/30 and no other natural 
isoflavans ((R)-sativan 143 or (R)-vestitol 116) could be prepared selectively. When 
tested for the synthesis of natural (R)-sativan by the same procedure, 2-(2,4-
dimethoxybenzyl)-2,3-dihydrobenzofuran-6-ol 144 was obtained as a 1:1 sideproduct 
along with the desired isoflavan (R)-sativan 143 from (R)-3-(2,4-
bis(benzyloxy)phenyl)-2-(2,4-dimethoxyphenyl)propan-1-ol 145 (Scheme 27). The 
sideproduct was explained to be formed from the bromide isomer 146, which was a 
product of the 2,4-(OMe)2C6H3 group migration in 147 after bromination by CBr4 and 
PPh3. Other unidentified sideproducts were also formed in the bromination step. 
Because of these sideproducts, the previously known Mitsunobu reaction (Scheme 28) 
had to be applied after debenzylation to construct the benzopyran ring135,145,146,148  of 
isoflavans other than equol. 2,4-Dimethoxy substitution in the B-aromatic ring in 147 
caused bromide group migration and formation of the sideproduct 146. 
 
 
 
 

 
 
Scheme 27. 2-(2,4-Dimethoxybenzyl)-2,3-dihydrobenzofuran-6-ol 144 as sideproduct 
in benzopyran ring formation after unstable bromination product by Takashima et 
al.115,155 
 
 
 
Scheme 28. Preparation of (R)-sativan 143 by using the Mitsunobu reaction in the 
final step.115,155  
 
 
The route from Takashima et al.115,155  suffered from not being a generally applicable 
and robust route to variously substituted isoflavans without the Mitsunobu reaction in 
the formation of the heterocyclic ring C. The procedure contained also energy 
consuming cryo chemistry in many steps and expensive reagents in larger scale. 
 
 
 
 
 
 
 
 
1.2.4 Synthesis of -methyldeoxybenzoins  
 
No synthesis methods for free polyphenolic -methyldeoxybenzoins 7 were available 
prior to our work or even to date. The lack of asymmetric synthetic methods of 
polyphenolic -methyldeoxybenzoins was especially obvious.  
   
 
1.2.4.1 Synthesis of racemic 	

 (1,2-diarylpropan-1-ones) 
Human urinary metabolites, O-DMA 22 and angolensin 168, have been prepared by 
multistep routes with protection groups. First angolensin 168 was prepared by a 
Friedel-Crafts reaction of resorcinol dibenzyl ether and 2-(4-
methoxyphenyl)propionic acid chloride.156 After debenzylation, racemic angolensin 
was obtained in a 13% yield. Corresponding 4-O-methyl ether of angolensin was 
produced from 1-benzyloxy-3-methoxybenzene in a 29% yield. The method was 
modified in our laboratory to prepare O-DMA 22 by using 1,3-dimethoxybenzene 169 
and 2-(4-methoxyphenyl)propionic acid 170 in polyphosphoric acid (PPA). After 
demethylation of 171 with 1M boron tribromide (BBr3 ) in dichloromethane (DCM, 
CH2Cl2), the product 22 was obtained in an 85% overall yield (Scheme 29).35 
 
 
 
 
 
Scheme 29. First synthesis of O-DMA 22 in our laboratory.35  
 
 
Angolensin 168 has also been prepared to give an 11% yield by 2-methylation and 
deprotection of 1-[2,4-bis(benzyloxy)phenyl]-2-(4-methoxyphenyl)propan-1-one.157 
In another report, angolensin was prepared by a base catalysed -C-methylation of 
deoxybenzoin 172, O-methylation being prevented by benzyl protection (Scheme 
30).158 After acidic debenzylation, angolensin was produced in a yield of about 60%. 
The preparation of these starting materials 172 and 173 clearly required further 
synthetic steps which lower the total yield. 
 
 
Scheme 30. Synthesis of angolensin 168 by a C-methylation of deoxybenzoin to give 
a yield of about 60%.158 
 
 
2,4-Dimethoxy-4’-hydroxy--methyldeoxybenzoin 174 has been prepared by a 
multistep route of eight steps.159 In this route, the starting tosylated dihydrochalcone 
175 was obtained in five steps, starting from 2,4-dimethoxyacetophenone 176 and 
anisaldehyde 177. Irradiation in dioxan at 350 nm gave the rearranged product 178, 
which was reduced with sodium cyanoborohydride (NaBH3CN) to the target product 
174 (Scheme 31). 
 
Scheme 31. Photochemical route to 2,4-dimethoxy-4’-hydroxy--
methyldeoxybenzoin 174.159 
 
As noted previously (Table 1), catalytic hydrogenation of isoflavones 1 with Pd/C at 
pH 11-12 has also been claimed to produce -methyldeoxybenzoins 7.110,111 
Previously, in our laboratory, unprotected natural -methyldeoxybenzoins 22 and 168 
have been prepared from corresponding phenolic isoflavones 16 and 19 with lithium 
aluminium hydride (LAH, LiAlH4) in tetrahydrofuran (THF) both in 42% yields 
(Scheme 32).160 By the same method, genistein metabolite 6’-OH-O-DMA 24 has also 
been prepared in a 66% yield.161 The method provided OH-substituted -
methyldeoxybenzoins easily except when there was no hydroxy substituent at the 
isoflavone 7-position. In such cases, prop-2-en-1-ols 179 were the main products. 
 
 
 
Scheme 32. Reduction of natural isoflavones with LiAlH4. 160,161 
 
In contrast to some earlier proposals,111 it is assumed that the initial step in these 
reductions is a 1,4-addition to the enone system, driven by the 4-oxypyrylium 
contributor I to the isoflavone structure (Scheme 33).160,I  This is followed by ring 
opening to a prop-2-en-1-one II, reduced by another 1,4-addition to give the 
deoxybenzoin enolates III, IV, or by an alternative 1,2-addition to give propenols VI. 
 
It was suggested that the effect of the 7-hydroxy substituent is to provide a further 
resonance contributor IV where the propenone carbonyl is lacking, thus favouring 
conjugate hydride attack at the propene terminus. 
 
 
 
Scheme 33. Proposed alternative reaction pathways for the LAH reduction of 
isoflavones with or without 7-OH-substitution by our group.160, I 
 
Regioselective methylations of O-DMA 22 were carried out during the course of this 
thesis (Scheme 34).162 
 
 
 
   
Scheme 34. Regioselective methylation of O-DMA. 162 
 
  
 
Regioselective methylation of O-DMA 22 offers an expedient route to mono- or 
dimethylated O-ether derivatives by appropriately adjusting the substrate : base : 
electrophile ratios according to pKa differences between these three phenolic groups. 
4’’-O-alkylation occurs via triphenolate anion formation by one equivalent of MeI in 
DMF to give angolensin 168 in a yield of 63%. In contrast, the 4’-O-alkylation to 180 
occurs by using only one equivalent of base and MeI due to the more acidic nature of 
the C-4’ site than the C-4’’. Bis(methyl ether) 181 can be prepared by using excess 
base and MeI in a 70% yield. Chelation effects obviously obstructed O-alkylation at 
C-2’ thus favouring O-alkylation at C-4’. 
The green chemistry approach by using microwave (MW) reactor and ionic liquid as 
co-solvent in Friedel-Crafts (F-C) acylation to prepare polyphenolic deoxybenzoins 
has also been studied in our laboratory.163 In case of -methyldeoxybenzoins such as 
O-DMA 22 (4’,4’’-dihydroxy--methyldeoxybenzoin), it did not crystallise, but had 
to be extracted by organic solvent and then purified by flash chromatography in a 
55% yield. In general, MW reaction times were short, and other deoxybenzoins than  
-methylated were easily crystallised from ionic liquids. 
 
The alkyl substituted -methyldeoxybenzoin 185 has been prepared by the palladium-
(II) acetate/n-BuPAd2 catalysed -arylation of ketone 186 with a non-activated 
chloroarene 187 (Scheme 35).164 More expensive Cs2CO3 was reported to be needed 
as base instead of K3PO4 to improve selectivity. 
 
 
 
Scheme 35. Preparation of alkyl substituted -methyldeoxybenzoin 185. 164 
 
More recently, the methoxy substituted -methyldeoxybenzoin 188 was prepared by a 
related Pd(II) catalysed -arylation of the ketone 189  by 4-OMe-chlorobenzene 190 
(Scheme 36).165,166 Aryl bromides gave twice as fast reactions, but yields were about 8-
10% lower. 
 
 
Scheme 36. Preparation of methoxy-substituted -methyldeoxybenzoin 188 by -
arylation of the enolisable ketone 189. 165,166 
Recently, monohydroxy--methyldeoxybenzoins 191-193  and deoxybenzoin 194 
were prepared by the spontaneous Truce-Smiles rearrangement starting from 
propiophenones 195 and 1-fluoro-2-nitrobenzenes 196 (Scheme 37).167 The 
intramolecular nucleophilic aromatic substitution was improved by the additional 
electron withdrawing groups, such as NO2, in the B ring. Methoxy-substitution in the 
para-position of acyl ring A prohibited the Truce-Smiles rearrangement and 
intermediate diaryl ether 197a, not deoxybenzoin 194, was the main product isolated 
in a yield of 65 % due to electronic effects. This indicates that the procedure is not 
valuable in producing natural methoxy substituted or polyphenolic derivatives such as 
O-DMA 22 and angolensin 168. 
 
Scheme 37. -Arylation of aryl ketones by the Truce-Smiles rearrangement.167 
 
1.2.4.2 Asymmetric synthesis of 1,2-diarylpropan-1-ones 
No reports about the asymmetric synthesis of natural polyphenolic -
methyldeoxybenzoins existed prior to our work. The asymmetric synthesis of a 
 
tetramethoxy substituted -alkyldeoxybenzoin has been published,168 reporting the 
use of chiral pseudoephedrine auxiliary 199 (Scheme 38). The pathway consisted of 
the asymmetric alkylation of an arylacetic acid 200 via its (S,S)-pseudoephedrine 
amide 201. After a hydrolysis of 202 to remove the chiral auxiliary, followed by a 
Friedel-Crafts acylation, the chiral non-racemic methoxy-deoxybenzoin, with the 
appropriate substitution at the benzylic carbon, was obtained.  
 
Scheme 38. Synthesis of enantiopure methoxy-1,2-diarylpropan-1-one 198.168 
 
 
(S,S)-Pseudoephedrine 199 was first introduced by Myers et al. (1994) as a practical 
chiral auxiliary for the synthesis of highly enantiomerically enriched -alkylated 
carboxylic acids, alcohols, aldehydes and ketones.169,170 The diastereoselective 
alkylation of pseudoephedrine amides was suggested to be derived from the  
electrophilic attack on the putative (Z)-enolate 205 (R syn to the enolate oxygen) from 
the same face (1,4-syn) as the carbon-bound methyl group of the pseudoephedrine 
auxiliary when the enolate is drawn in a planar, extended conformation (see Fig. 6).  
 
Fig. 6. Mnemonic for pseudoephedrine amide enolate 205 alkylation.169,170 
 
Vicario et al.168 suggested that a more rigid structure than 206 for the reaction 
intermediate should be required in order to explain the high degree of stereoselection 
obtained. It was concluded that lithium ions, from LiCl, must be coordinated to the 
enolate oxygen and lithium alkoxide in the pseudoephedrine moiety through a 
bridging species present in the reaction media, such as the solvent or a chlorine anion 
from LiCl as drawn in 207 (Fig. 7).    
 
 
Fig. 7. Proposed mechanism in the asymmetric alkylation of pseudoephedrine derived 
amide enolate 207. X denotes solvent, Cl or (iPr)2NH  molecules.168 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	
2. AIMS OF THE STUDY  
 
The objective of this study was to synthesise and identify plant derived isoflavone 
metabolites formed in the intestinal track in human, and other mammals such as  
ruminants, consuming a phytoestrogen rich diet. Interest in isoflavone metabolism 
derives from the anticipated beneficial biological effects of phytoestrogen metabolites 
on human and animal health. Possible adverse effects also require further research. 
The isoflavonoids synthesised in this thesis were used as authentic reference 
compounds in clinical chemistry studies to identify and quantify the metabolites in 
body fluids and tissues. The synthesis of these isoflavonoids was also important for 
the biological activity studies. 
 
The main goal in the synthetic work was to develop atom economical and expedient 
routes to produce free hydroxy substituted or phenolic isoflavonoids, which were 
unknown, according to chemical literature, prior to this work. For example, no 
published methods were available for reducing hydroxysubstituted isoflavones with 
hydride reducing agents in general. In particular, there were no methods to prepare 
enantiopure synthetic reference compounds for the characterisation of new chiral 
metabolites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 $
3. RESULTS AND DISCUSSION  
 
3.1. Isoflavone reductions by hydride reagents and hydrogenationsI, II, IV 
 
An expedient one-pot synthesis of various polyhydroxy isoflavones 1 from an 
appropriate phenol and aryl acetic acid had been developed earlier in our group.93  The 
availability of these various polyphenolic isoflavones as starting materials offered a 
practical approach to study hydride reductions and hydrogenations by different 
available reagents in producing reduced isoflavonoid structures 2-5 and 7 (for the 
summary of the results see Scheme 39 below).  
 
 
 
Scheme 39. Summary of the selective isoflavone reductions achieved in this study. 
 
In general, sodium borohydride (NaBH4) is the most used reagent in reducing 
isoflavone 1 or isoflavan-4-one 2 skeletons according to the chemical literature. 
However, published results covered only unsubstituted or protected starting materials 
with variable product combinations formed (isoflavan-4-one 2 or cis- and/or trans-
isoflavan-4-ols 3 or sometimes isoflav-2-en-4-ol 81 (Fig. 5)). In addition, the product 
characterisations were contradictory from one study to another as already discussed in 
section 1.2.1. This study describes the conformational equilibria of diastereomeric 
pairs of isoflavan-4-ols determined by NMR and clarifies the isoflavone hydride 
reductions in comparison to the prior ambiguous results reported in the literature.I,II,IV 
 
 

The hydride reduction of ,-unsaturated ketones, such as the isoflavone ring C, can 
take place by two alternative pathways. Addition to the conjugated double bond 
proceeds by 1,4-addition to first give an isoflavan-4-one 2, which is further reduced to 
an isoflavan-4-ol 3. Alternatively, the reduction can follow the 1,2-addition pathway 
to the carbonyl group. For example, the claimed isoflav-2-en-4-ols 81 were reported 
in the literature to be 1,2-addition products.  
 
During the experimental work, we discovered that the addition pathway of various 
hydride reagents to isoflavones 1 mostly involves the 1,4-pathway in contrast to the 
ordinary non-flavonoid -alkoxy-,-unsaturated ketones, which favour 1,2-addition. 
Various products to be formed were dependent on the following factors:  
1) the hydride reagent (electrophilic/nucleophilic, steric effects),  
2) the substrate, (free OH or not; especially 7-position phenolic group was important 
in LAH reductions and determined whether a 1,4- or 1,2-addition took place) or  
3) the pH of the reaction media. Under basic conditions with NaBH4 in EtOH 1-(2-
hydroxyaryl)-2-arylprop-2-en-1-ols 211 were formed as sideproducts among 
isoflavan-4-ols 212, 213 (Scheme 40). The addition of boric acid blocked the 
sideproduct formation. 
 
 
Scheme 40. Reduction of non-phenolic isoflavones with sodium borohydride. 
 
The hydride addition reactions tested followed mainly the initial 1,4-addition route to 
give the isoflavan-4-one enolate. In a hydroxylic solvent, or even on workup under 
basic conditions, the ketone is generated, and reduced further to the saturated alcohol 
(NaBH4). The presence and number of phenolic or alkoxy groups in the substrates 
does not have a major effect on these reductions except in the case of NaBH4 
reduction, which fails completely presumably due to solubility reasons, and LAH 
reduction where the outcome depends on the presence or absence of an OH 
substituent at C-7. -Methyldeoxybenzoins could be prepared selectively by the 1,4-
addition if starting isoflavone had the 7-hydroxy substitution.I In the case of 7-
methoxy or hydrogen substitution in the starting isoflavone, 1-(2-hydroxyaryl)-2-
arylprop-2-en-1-ols 211 were the main products observed after 1,2-addition (Scheme 
40 above).  
A rare exception for the typical 1,4-addition by borohydrides was observed with the 
bulky 9-BBN. It was found to react by 1,2-addition to the carbonyl group to give 
isoflav-3-ene and not the 1,4-addition product isoflavan-4-one with both protected 
and free phenolic isoflavones as described in section 3.3 Scheme 43. IV 
 
The previously claimed potential 1,2-addition product isoflav-2-en-4-ol 81 was not 
formed in any hydride addition reaction.I In addition, the dehydration of polyphenolic 
isoflavan-4-ols 3 by acidic treatment was not selective in producing isoflav-3-enes 5 
as previously claimed by others.VII  
Isoflavans 4 were only obtained by Pd catalysed hydrogenations (more details in 
section 3.4.1), not as hydride reduction products.  
  
3.2. Synthesis of trans- and cis-isoflavan-4-olsI, II 
 
As no diastereoselective syntheses of polyphenolic trans isomers of isoflavan-4-ols 3 
were available or discovered by us, we developed an RP HPLC method to separate 
the two diastereomers from each other.II Diastereopure reference compounds are 
needed for the identification of natural metabolites as biological activities are 
determined to various degrees by the adopted conformations of the substrates.171 
Trans-isoflavan-4-ols 215, 216 and cis-isoflavan-4-ols 217, 218 were separated from 
the prepared diastereomixtures by HPLC or column chromatography in order to study 
their conformational equilibria. Intermediate isoflavan-4-ones 219, 26 were prepared 
from corresponding isoflavones 1, 16 by catalytic transfer hydrogenation reactions as 
described in scheme 41.  
 
 
 
Scheme 41. The structures of the isoflavones, isoflavanones and the isoflavanols 
(trans- 215, 216 and cis- 217, 218). Reaction conditions: (a) Pd/C, NH4OCHO, 
MeOH, reflux; (b) Li(t-BuO)3AlH (10 eq.), THF, 25-30oC (219   215, 217).  
(c) LiBH4, THF, 0oC (26   216, 218). 
 
 
 
Scheme 42. The generalized half-chair conformations adopted by the isoflavan-4-ols 
looking across the heterocyclic ring towards the fused aromatic ring. Cis isoflavan-4-
ols can be anancomeric with only one conformer predominating61 whilst the trans 
isoflavan-4-ols are an equilibrium mixture of diequatorial and diaxial half-chair 
conformations.II 
 
 
 
 
 
3.3. Synthesis of Isoflav-3-enesIV 
 
7,4’-Dihydroxyisoflav-3-ene 17 (dehydroequol) was expediently prepared from 
readily available daidzein 16 by reduction with 9-BBN in THF (Scheme 43) in one 
step. Dehydroequol has previously been prepared either by multistep routes or 
unselectively together with corresponding isoflav-2-ene by the Clemmensen reaction 
(Scheme 6). 
 
  
Scheme 43. Approach to the synthesis of dehydroequol 17 and O,O'-
dibenzyldehydroequol 58. Reaction conditions: i. 9-BBN, THF, rt, 15h, 50-60%; ii. 
K2CO3, BnCl, DMF, refl., 90%.IV 
 
Isoflav-3-enes 17 and 58 were useful substrates for the asymmetric hydrogenation 
experiments to prepare enantiopure polyphenolic isoflavans. The chiral iridium-
PHOX precatalysts 231, 232 (Scheme 45) and 235, 236 (Fig. 8) were found to be 
highly enantioselective (ee 80-93 %) towards hydrogenations of isoflav-3-enes tested 
(see Section 3.4.2). 
 
 
3.4. Synthesis of IsoflavansIV, VII 
 
3.4.1 Racemic polyphenolic isoflavansVII 
 
Due to problems caused by Pd on charcoal (varying reactivity between different 
batches, partly because of variable amounts of HCl traces left)172, another reagent was 
used in this work. Palladium on barium sulfate proved to be an excellent reagent for 
the heterogenous hydrogenation of isoflavones to produce polyphenolic isoflavans 
(Scheme 44). Ethanol (96%) was already proved to be a superior solvent for the 
reaction over AcOH or other solvents.117 Starting isoflavones are poorly soluble in 
EtOH, but product isoflavans are soluble, thus offering an easy separation of traces of 
starting material from the raw product by filtration. 
 
 
 
 
 
Scheme 44. Preparation of isoflavans from unprotected isoflavones.VII 
 
   
The most used method to prepare racemic isoflavans has been the hydrogenation of 
isoflavones with Pd/C. The problems with catalytic hydrogenation reactions of 
isoflavones have been in many cases the need to use protection of phenolic hydroxy 
groups, the unselectivity, moderate yields and many reaction steps. In this study, the 
objective was to try to optimise the Pd-catalysed hydrogenation of unprotected 
isoflavones, which are easily obtained by the one-pot Friedel-Crafts acylation 
developed in our laboratory.93 In a previous study to prepare isoflavans in our 
laboratory, it was concluded that excess Pd on charcoal (isoflavone:Pd metal ratio, 1 
mol-eq : 1.6 mol-eq) produced the best yields.117 The Pd/C was not an optimal reagent 
though, because results varied when  different batches or suppliers of the reagent were 
used.  For example, it has been discovered in our laboratory that certain commercial 
batches of the Pd/C actually contained large quantities of PdCl2 which is reduced to 
Pd and HCl.172 Thus, a better carrier for the palladium metal was needed. 
 
 
3.4.2. Enantiopure polyphenolic isoflavansIV 
 
At the time of this thesis work, there were no prior reports about the synthesis of 
enantiopure polyphenolic isoflavans. The main objective was to develop an 
enantioselective synthesis of isoflavans, especially natural S-equol and its nonnatural 
enantiomer R-equol, for biological studies. The existing asymmetric approach with 
chiral auxiliaries developed by Versteeg et al.145,147,148 (Scheme 23) was not valuable 
in producing free hydroxy substitution through demethylation since known methods 
were not described at that time and would have added even more steps to an already 
long route. 
 
Only recently, a total synthesis of enantiopure equol was reported to give a less than 
10% overall yield,114 There is also a recent study,173 where a certain human anaerobic 
bacteria strain was used to convert dihydrodaidzein 26, a known isoflavone metabolite 
itself, to (S)-equol 29. 
 
Another approach was taken in this study, namely the asymmetric organometal 
catalysed hydrogenation of isoflav-3-enes 5, which are conveniently prepared from 
readily available isoflavones 1 as shown in the previous section (Scheme 46).  
 
 
Asymmetric hydrogenation of 58 with 3 mol% of iridium PHOX-catalysts 231 or 232 
(preparation of  231 and 232 in Scheme 45) in dichloromethane (DCM) yielded 
dibenzyloxyequols 233 or 234 successfully, in yields of approximately 90%. 
Alternatively, the commercial threonine derived iridium PHOX complex 235 yielded 
233 in a 90% yield. 
Given the limited solubility of even dibenzyloxydehydroequol 58 in DCM, catalyst 
loading was, to some extent, higher than in some earlier asymmetric olefinic 
hydrogenations with similar Ir-PHOX catalysts (0.3-3 mol%). With 58, 3-4 mol% 
precatalyst loadings were required to achieve good yields (ca. 90%) and 
enantioselectivities (ee 92-93%) at ambient temperature. Almost full conversions 
were also achieved by lower catalyst loadings, but ee values decreased to 40%. (S)-(-
)-equol 29 and (R)-(+)-equol 30 were obtained after debenzylation of protected equol 
enantiomers 233 and 234. 
7,4’-Dihydroxyisoflav-3-ene 17 (dehydroequol) was not soluble in DCM
 
at a practical 
synthetic level, thus the asymmetric hydrogenation of 17 was not possible under 
similar conditions as for 58. The addition of co-solvent such as acetone repressed the 
catalysis as indicated by calculated results174 although the solubility of 17 would have 
been much better.  
Two commercially available threonine derived iridium PHOX catalysts 235 and 236 
were also tested. Both gave (R)-(+)-equol 30 with good yields and ee 80 - 93% 
starting from 58 (Table 3).IV 
 
 
Scheme 45. Synthesis of iridium-BARF complexes 231 and 232 via corresponding 
chiral PHOX ligands.IV ORTEP plot for 231 in Fig. 9. 
 
 
 
 
Fig. 8. Commercial threonine based iridium PHOX BARF-catalysts 235 and 236. 
 
Fig. 9. X-ray crystal structure of the synthesised  (S)-PHOX -based iridium BARF 
complex 231. ORTEP plot.  
 
 
 
Table 3. Enantioselective hydrogenation experiments of 58 with use of different 
Iridium PHOX catalysts 231, 232, 235 and 236. All experiments gave yields about 
90%. 
experiment starting 
material 
solvent catalyst T / 
oC 
P / 
bar 
reaction 
time / h 
mol% 
catalyst 
eea abs. 
conf. 
1 58 DCM 231 rt 50 42 3 92  (R) 
2 58 DCM 231 120 50 15 2 40  (R) 
3 58 DCM 232 rt 50 15 3 92  (S) 
4 58 DCM 232 rt 50 42 3 92  (S) 
5 58 DCM 235 rt 50 15 4 93  (R) 
6 58 DCM 236 rt 50 15 3 80  (R) 
aThe ee values were determined by chiral HPLCIV and the absolute configuration was 
determined by single crystal XRD analysis (Fig. 10, Scheme 47).  
 
 
 
 
Scheme 46. Synthesis of (S)-(-)-equol 29 and (R)-(+)-equol 30 from 7-O,4’-O-
dibenzyldehydroequol 58.IV  
 
The absolute configuration of the synthesised (S)-(-)-equol 29 was determined by a 
single crystal XRD measurement of the diiodo-(S)-equol derivative 29b (Fig. 10, 
Scheme 47), prepared from enantiopure (S)-(-)-equol 29 by the selective diiodination 
developed during this thesis to improve the accuracy of the XRD analysis. 
 
 
Fig. 10. X-ray crystal structure of the synthesised (S)-(-)-6,8-diiodoequol 29b. 
ORTEP plot.  


 !  synthetic (S)-(-)-equol 29 to (S)-(-)-6,8-diiodoequol 
29b to be used in the single crystal XRD analysis in determining the absolute 
configuration of the prepared parent enantiopure (S)-(-)-equol 29 (more details in 
Experimental section). 
In comparison with other published methods, this asymmetric hydrogenation of 
dehydroequol derivatives offers a competitive method for the preparation of bioactive 
chiral isoflavans. 
 
 
OHO
OH
OHO
OH
29b
N-iodosuccinimide
DMF, 0oC to rt
49%29
I
I
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3.5. Synthesis of  -methyldeoxybenzoinsVII 
 
No asymmetric synthesis of polyphenolic -methyldeoxybenzoins 7 was available 
prior to this work. However, the reaction of chiral 2-arylpropionic acids 241, 242 with 
recorcinol 49 offered an expedient route to chiral polyphenolic -
methyldeoxybenzoins by the Friedel-Crafts acylation procedure (more details in 
section 3.5.2).VII A number of racemic polyphenolic "##
#"" VII 
3.5.1. Polyphenolic -methyldeoxybenzoinsVII 
 
Previously, O-DMA 22 has been prepared from 1,3-dimethoxybenzene 169 and 2-(4-
methoxyphenyl)propionic acid 170 in PPA giving an 85% yield as described in 
section 1.2.4.1 (Scheme 29) or by LAH reduction in THF of daidzein in 42% yield 
(Scheme 32).  
 
By adapting the boron trifluoride etherate (BF3.OEt2) catalysed Friedel-Crafts 
acylation, developed for the one-pot synthesis of unprotected polyphenolic 
isoflavones previously in our laboratory, also a number of different polyphenolic -
methyldeoxybenzoins 22, 243-248 from the corresponding 2-arylpropanoic acids 256 
a-d and polyphenols could be prepared only in one step and in good yields (ca. 70-
90%) (Scheme 48, for more details, see section 3.5.1).VII 
 
 
 
 
R1, R2, R3=H  256a R4,R5=H  22   R1,R2,R3,R4,R5=H 
R1=OH, R2,R3=H 256b R4=OH, R5=H 243 R1,R2,R3,R4=H, R5=Me 
R1=H, R2=Me, R3=OMe
 
256c R4=H, R5=Me 244 R1,R2,R3,R5=H, R4=OH 
  256d R4=OMe, R5=Me 245 R1=OH, R2,R3, R4,R5=H 
     246 R1,R4=OH, R2,R3,R5=H 
     247 R1,R4=H, R3=OMe,R2,R5=Me 
    248 R1=H, R3,R4=OMe, R2,R5=Me
 
 
Scheme 48. Preparation of polyphenolic O-DMA derivatives by a direct F-C 
acylation without protection of phenolic groups. VII 
 
Only recently, Goto et al. (2009) used an identical approach to prepare a number of 
different OMe- or OH-substituted -methyldeoxybenzoins for use in radical-
scavenging activity studies.119  
 
 
 $
 
3.5.2. Enantiopure -methyldeoxybenzoins [1,2-(diaryl)propan-1-ones]VII  
 
The asymmetric synthesis of tetramethoxy substituted -methyldeoxybenzoins (no 
substitution in the C-2 position in ring A as in natural O-DMA derivatives) has been 
published,168 where the use of chiral pseudoephedrines was also introduced. However, 
the methoxy-substitution is not really effective in producing polyphenolic O-DMA 
derivatives owing to the partial racemisation in the deprotection step as demonstrated 
in this study by the demethylation of diphenolic (R)-(-)-angolensin 249 (described in 
more detail at the end of this section).VII  
 
In this study, a natural diphenolic (R)-(-)-angolensin 253 and its enantiomer (S)-(+)-
angolensin 255 were prepared for the first time by adapting the approach already 
described in the previous section, using the one-step BF3-etherate catalysed Friedel-
Crafts acylation between resorcinol 49 and a chiral acid 241/242. 
 
The chiral acids 241/242 were first prepared by using pseudoephedrine 199 and its 
enantiomer 210 as chiral auxilliaries (XC) (Scheme 49, Table 4; for more details see 
section 5. Experimental).  
 
The pseudoephedrine amide enolates 251 and 252 were prepared from commercially 
available 4-methoxyphenylacetic acid (253) after in situ acid chloride formation and 
by using (R,R)-(-)- or (S,S)-(+)-pseudoephedrines as chiral auxiliaries.168,VII The 
diastereoselective methylation of the formed pseudoephedrine amide enolates was 
readily performed by electrophilic attack of MeI after dianion formation with LDA in 
the presence of LiCl in THF at –78oC (2h) and at 0oC for 6 hours to produce 
diastereopure -methylated pseudoephedrine amides 254 and 255 (d.e. >95% by 1H 
NMR). Chiral auxiliaries were cleanly removed by acid hydrolysis yielding 241 and 
242 in a yield of approximately 70% after a standard aqueous acid-base extraction and 
recrystallisation from aq. MeOH. 
 
The chiral acid 242 has been previously prepared by the enzymatic hydrolysis of 
racemic -methylarylacetonitrile using Rhodococcus sp. CGMCC 0497 in an 
unspecified yield,175 but the other chiral acid 242 has not been prepared before. 
 
The enantiopure angolensins 249 and 250 were prepared by the F-C acylation reaction 
of commercially available resorcinol 49 and the chiral acid 241 or 242.  The reaction 
conditions were equal to already described method for the preparation of racemic O-
DMA derivatives in the previous section. The overall yields of (R)- and (S)-
angolensins 249 and 250 were 44% and ee 97-98%. 
The absolute configuration of the prepared (-)-angolensin 249 was determined to be R 
by a single crystal X-ray (XRD) measurement (Fig. 11). The opposite enantiomer was 
concluded to be (S)-(+)-angolensin 250. (R)-(-)-angolensin has also been isolated 
from the plant Pterocarpus angolensis, but no x-ray data was reported then.176,177  
Demethylation of the first prepared diphenolic (R)-(-)-angolensin 249 or (S)-(+)-
angolensin 250 (Scheme 49) by BBr3 in DCM, as described for racemic angolensin in 
Scheme 29, led to partial racemisation according to our experience (ee decreased from 
 

98% to 53%)VII and therefore this approach was not useful for the preparation of 
enantiopure triphenolic (R)-O-DMA or the other enantiomer (S)-O-DMA.VII  
 
 
 
Scheme 49. First synthesis of enantiopure (R)-(-)-angolensin 249 and (S)-(+)-
angolensin 250 developed during this work. Reagents and conditions: i) SOCl2, 
toluene, refl.; ii) (R,R)-(-)-/ (S,S)-(+)-pseudoephedrine, Et3N, THF, -20oC, ~85%; iii) 
LDA, LiCl, THF, -78oC; iv) MeI, THF, 0oC, ~88%; v) dioxane, 4M H2SO4, refl., 69-
70%; vi) resorcinol, BF3OEt2, 79-81% (Table 4 yields and de and ee in more detail). 

Fig. 11. X-Ray crystal structure of the synthesised (R)-(-)-angolensin 249. ORTEP 
Plot. 
Table 4. Stereoselectivities (diastereomeric excess, de or enantiomeric excess, ee) and 
yields obtained in the asymmetric synthesis of the enantiopure angolensins 249, 250.  
product yield 
(%)d 
de 
(%)a 
product yield 
(%) 
product 
 
yield 
(%)d 
ee 
(%)b 
tR(min) 
254c 87 >95 241c 69 249 R-(-)-
angolensin 
79 98 13.5 
255c 88 >95 242 70 250c S-(+)-
angolensin 
81 97 27.5 
a
 Determined by 1H NMR.  b Determined by chiral HPLC; Ultron ES-OVM for 249 
and 250; c new compound.   dafter column chromatography purification. Analysis 
conditions described in section 5. Experimental. 
 
 
3.6. Isoflavonoids in biological studies 
  
Table 5. Isoflavonoid metabolites identified from mammalian species in conjunction 
with the synthesis research project and their biomedical studies. 
Isoflavonoid  
/ reference 
Body fluids found 
/ reference 
Biomedical studies / reference 
(S)-equol (29)IV Serum of ewesIII Receptor binding activity of S-
enantiomer vs. rac-mixtureV 
Rac-O-DMA (22)VII Human urineVI 
Cow milk26 
ODMA producing ability in manVI 
Rac-equol (15)VII Human urineVI 
Cow milk26 
Equol producing ability in manVI 
Trans-7,4’-
dihydroxyisoflavan-
4-ol I, II 
Not found Antitumor activity against human 
prostate cancer cells in vitro were 
comparable to genistein and cis-isomer. 
61
 
cis-7,4’-
dihydroxyisoflavan-
4-ol (28)II 
Human urine45 Antitumor activity against human 
prostate cancer cells in vitro were 
comparable to genistein and trans-
isomer.61 
 
 
 
3.6.1. S-equol 29 determination from serum of ewesIII 
 
In this study (S)-(-)-equol 29 has been identified from the serum of ewes after red 
clover feeding for the first time using the enantiopure reference compound.III  In the 
same study O-DMA 22 was also identified. Coinciding with the publication of this 
paper, a report about X-ray single-crystal analysis of (-)-S-equol 29 isolated from rat 
faeces in vivo was published.154 Simultaneously, human intestinal bacteria was 
reported to solely produce the S-enantiomer of equol. 178 
 
Quantitative HPLC-DAD determination of isoflavonoids from red clover fed ewe 
serum showed that equol 15 was the main metabolite present (7.7 mg mL-1). Thus the 
chiral HPLC analysis was developed to determine absolute configuration of the 
natural enantiomer by the aid of prepared chiral reference compounds.III, IV Thus, the 
natural equol was proved to be solely the S-enantiomer 29. 
 
 
3.6.2. ODMA 22 and equol 15 in human isoflavone metabolism studies  
 
Only about half of the human population are able to convert isoflavones to further 
metabolites such as equol 15and 80-90% are able to produce O-DMA 22.179-184       
For example, rats, chimpanzees and mice are proved to be equol producers and no 
interindividual differences are found.185 Bovines are also able to convert daidzein to 
equol and excrete it in their milk.105 Our interdisciplinary study186 about the 
concordance within an individual for the equol-producer and O-DMA producer 
 
phenotypes were measured at two time points (T1, T2), 1-3 years apart. Phenotypes 
were ascertained by analyzing equol and O-DMA using GC-MS in a spot urine 
sample collected after 3 days of soya (source of daidzein) supplementation. In ninety-
two individuals, 41% were equol producers at T1 and 45% were equol producers at 
T2, and 90% were O-DMA producers at T1 and 95% were O-DMA producers at T2. 
These results suggest that these phenotypes are stable in most individuals over time, 
providing a useful biomarker for evaluating disease risk associated with harboring 
particular intestinal bacteria responsible for the metabolism of the soy isoflavone 
daidzein. Another study from our group187 revealed the differences between equol and 
O-DMA producing abilities among Caucasian and Korean American women and 
girls. The Caucasian population had a lower equol-producing prevalence, but a higher 
O-DMA producing ability  compared to Korean Americans. These findings support 
the reports that, compared with Western populations, Asian populations have a higher 
equol-producer prevalence, which may be in association with a lower mortality due to 
hormonal cancers. Synthetic equol has also been used in studies about serum steroid 
hormones, sex hormone-binding globulin concentrations, and urinary hydroxylated 
estrogen metabolites in post-menopausal women in relation to daidzein-metabolizing 
phenotypes. VI,188  
 
   
3.6.3. Biological activity of S-equol 29 vs. rac-equol 15 in vitroV  
 
A comparison study of the effects of the racemic equol 29 with that of S-enantiomer 
29 on the growth, invasion and DNA integrity of breast and prostate cells in vitro was 
performed. Both racemic and pure S-equol inhibited the growth of the breast cancer 
cell line MDA-MB-231 (>10 mM) and the prostate cancer cell lines LNCap (>5 mM) 
and LAPC-4 (>2.5 mM). The compounds also showed equipotent effects in inhibiting 
the invasion of MDA-MB-231 and PC-3 cancer cells through matrigel. S-equol (1, 10, 
30 mM) was unable to prevent DNA damage in MCF-7 or MCF-10A breast cancer 
cells following exposure to 2-hydroxy-4-nonenal, menadione or benzo(a)pyrene-7,8-
dihydrodiol-9,10-epoxide. On the contrary, racemic equol 15 (10, 30 mM) prevented 
DNA damage in MDF-10A cells following exposure to 2-hydroxy-4-nonenal or 
menadione. These findings indicate that racemic equol has strong antigenotoxic 
activity in contrast to the single S-enantiomer implicating the R-, rather than 
metabolic S-enantiomer as being responsible for the antioxidant effects of equol. 
These results may have implications on the in vivo chemoprotective properties 
attributed to equol. 
 
     
3.6.4 Equol quantitation in organic skimmed Finnish cow milk26 
 
 
The isoflavonoids, equol rac-15, formononetin 19, daidzein 16, genistein 18, 
biochanin A 20 and O-DMA 22, were analyzed from commercial cartons of skimmed 
Finnish cow milk by HPLC- (DAD)-FL. Identification was confirmed by comparing 
the UV-spectra of the eluting peaks with authentic reference compounds. Flavone 14 
was used as a standard to calculate recovery, which was 80% +/- 6%. According to 
analysis 411 +/- 65 ng/mL of equol 15 and traces of formononetin 19 and daidzein 16 
 
were detected in organic skimmed milk whereas conventionally produced milk 
contained only 62 +/- 16 ng/mL of equol and no formononetin or daidzein. Results 
indicate that isoflavone rich red clover feed used in Finnish organic farming is 
responsible for high levels of equol in cow’s milk. Discovery indicates that more 
studies about the health effects of organic products should be conducted due to 
growing consumption of these products. 
 
4. CONCLUSIONS 
 
In this thesis work, a direct and highly enantioselective route toward enantiopure (R)-
equol 30 and (S)-equol 29 was developed. Both of these equol enantiomers are found 
to have positive biological activity in mammals. In addition, the first direct and 
efficient synthesis of dehydroequol 17, a potent anticancer drug, by a one step 
synthesis from readily available daidzein 16, was presented. The  first reported 
enantioselective synthesis of enantiopure angolensins (249, 250) has also been 
described. The method also offers a synthesis route towards enantiopure O-DMA 22 
by modifying the 4’’-O-protection group in chiral acids to, for example, silyl or 
benzyl which are more easily cleaved than methyl. Synthesis of chiral (R)-O-DMA 
and its enantiomer are under further development to be used in the identification of 
the metabolic eutomer. 
Other polyhydroxy isoflavonoids have also been synthesized to be used as standards 
in analytical and metabolic studies of these natural nutrition based metabolites. 
 
In this study, the isoflavone hydride reductions were clarified in comparison to the 
prior ambiguous results reported in the literature.  
 
The discovery of (S)-equol 29 from the serum of ewes by using authentic reference 
compound clarified the metabolism track of daidzein 16 and formononetin 19 in these 
production animals.  
 
The described metabolic findings suggested that more studies about the biological 
effects of these metabolites are needed, since for example cows’ milk, and also blood, 
are used in the human food industry as ingredients, and they are direct sources of 
reduced isoflavonoids in human nutrition. Effects and biologically safe dosages of 
(S)-equol 29 and other mammalian metabolites to human health are still to be 
discovered. 
 
 
5. EXPERIMENTAL  
 
The experimental part of the work that has not been included in the publications I-VI 
is described in this section. 
 
General Experimental Procedures  
NMR spectra were recorded on a Bruker 500 Avance  or a Varian 300 Mercury Plus 
spectrometer. 1H-NMR (500 MHz) and 13C-NMR (125 MHz or 75 MHz) spectra were 
referenced to tetramethylsilane (TMS) at 0.00 ppm. J values are reported in Hz. Low 
and high resolution mass analyses were recorded on a  JEOL JMS SX102 mass 
spectrometer operating at 70 eV. TLC was conducted on Merck silica gel 60 F254 
 
plates, and Merck silica 60 (0.040-0.063 mm, 230-400 mesh) was used for flash 
chromatography. Chiral HPLC analysis for ee determinations were performed on a 
Waters model 996 HPLC instrument with Photodiode Array detector and Waters 717 
plus autosampler. Measurement conditions: Ultron ES-OVM, 250 x 4.6mm, ID., 10 
mm particle size, MeOH-phosphate buffer (pH 4.65), 25:75 as eluent flow rate 
1mLmin-1 for (R)- and (S)-angolensin. Cyclobond I 2000 RSP column, 250x10 mm, 
10 mm, Astec guard column system 4 mm ID, 2 cm lenght,  30:70 ACN:0.1% formic 
acid 3.5 mLmin-1 for (R)- and (S)-O-DMA. Melting points were determined in open 
capillary tubes, with an Electrothermal apparatus, and are uncorrected. Specific 
optical rotations were measured with a Jasco DIP-1000 Digital Polarimeter. THF was 
purified and dried by refluxing in continuous distillation apparatus with sodium and 
benzophenone as an indicator prior to use. Triethyl amine, toluene and 
dichloromethane were distilled over CaH2.  
 
5.1 Preparation of (S)-6,8-diiodo-7,4’-dihydroxyisoflavan 29b 
Chiral (S)-equol 29 (0.024g, 0.10 mmol) and sodium iodosuccinimide (0.023g, 0.10 
mmol) were dissolved in dry DMF (1 mL) under argon atm and stirred at 0oC for 17h. 
The reaction was quenched by adding water followed by extraction with diethyl ether 
and evaporation to dryness. The raw product was a light yellowish oily prepicipitate 
and was flash chromatographed in silica gel by eluting with DCM.  The combined 
DCM fractions were evaporated to dryness to give 0.024g (0.049 mmol, 49.0%) of 
29b, which was recrystallised from hexane/diethyl ether to give white crystals, which 
could be used in the single crystal XRD measurement of the absolute configuration of 
the parent (S)-equol 29 (Fig. 10) 
 (300 MHz, d6-acetone) 4.08 (dd, J 10.5, 10.5, H-2 ax), 4.37 (ddd, J 10.5, 3.6, 2.1, H-
2 eq), 3.11 (dddd, J 10.5, 10.6, 5.7, 3.6, H-3 ax), 2.96 (ddd, J 15.6, 10.6, 1.0, H-4 ax), 
2.91 (ddd, J 15.6, 5.7, 2.0, H-4 eq), 7.50 (s, H-5), 7.17 (d, J 8.6, H-2’,6’) 6.83 (d, J 
8.5, H-3’,5’), 7.69 (br s, OH), 8.28 (br s, OH); (EI) m/z (rel. int):  M+ 493.9 (100%), 
368.0 (50%). HRMS C15H12O3I2 requires 493.8876, observed 493.8879.  
 
 
5.2 Preparation of chiral 2-(4-methoxyphenyl)-propionic acids 241 and 242.  
Commercial 4-methoxyphenyl acetic acid (5.9 g, 0.030 mol) was converted to it’s 
corresponding acid chloride by  refluxing with SOCl2 (0.044mol, 5.5mL) in toluene 
(78mL) and further to the  amides 251 and 252 by using either (S,S)-(+)- or (R,R)-(-)-
pseudoephedrine (4.95g,   0.030mol) and Et3N (5.0mL) in THF (150mL)  at -20oC for 
4.5 hours in 88% yield. Amides 251 and 252 were asymmetrically methylated using 
LDA (0.053mol), LiCl (6.70g, 0.158mol) and MeI (0.029mol, 1.82mL) in THF 
(70mL) in –78oC to 0oC to produce 254 and 255 with a yield of 89%. Chiral 
auxiliaries were cleanly removed by refluxing with 4M HCl in dioxane yielding 241 
and 242 in a yield of approximately 70%. 
 
(-)-(1R,2R)- and (+)-(1S,2S)-N-(2-Hydroxymethyl-2-phenylethyl)-N-methyl (4-
methoxyphenyl) acetamide 251 and 252. White plates, 88%, mp 131oC (toluene) 
lit.:189 130-132oC.   [a]D28=-108.0 (c. 0.2, CH2Cl2) 251,  [a]D27=+108.0 (c. 0.2, CH2Cl2) 
252. 1H and 13C NMR and IR as reported.189 (EI) m/z (rel. int): 313 (M+, 0.5), 295 ([M-
 
H2O]+, 100), 206 (55), 148 (42), 121 (58); (M–H2O)+ C19H21O2N  requires 295.1572 
observed 295.1570. 
 
(-)-(1R,2R)- and (+)-(1S,2S)-N-(2-Hydroxymethyl-2-phenylethyl)-N-methyl-2-(4-
methoxyphenyl) propionamide 254 and 255. Colourless oil 89%, [a]D29=-92.0 (c. 
0.2, CH2Cl2) 254 and [a]D29=+92.0 (c. 0.2, CH2Cl2) 255. 1H NMR d (2.75:1 rotamer 
ratio, * denotes minor rotamer peaks, 300 MHz CDCl3) 0.52* (d, J=7.0, 3H), 1.10 (d, 
J=7.0, 3H), 1.37 d, J=7.0, 3H), 2.67 (s, 3H), 2.90* (s, 3H), 3.67-3.72 (m, 3H), 3.73* 
(s, 3H), 3.77 (s, 3H), 4.0-4.58 (m, 4H), 6.78-6.85 (m, 2H), 7.09-7.16 (m, 2H), 7.24-
7.40 (m, 5H); 13C NMR d (3:1 rotamer ratio, * denotes minor rotamer peaks, CDCl3, 
75 MHz ) 14.1, 14.6*, 20.8, 21.0*, 42.7*, 43.3, 55.3, 57.8, 75.5*, 76.4, 114.3, 126.4, 
126.8, 127.3*, 127.6, 128.2, 128.7*,133.5, 134.5*, 141.5*, 142.3, 158.2*, 158.4, 
171.2, 175.1*, 176.2;   (EI) m/z (rel. int): 327 (M+, 1%), 309 ([M-H2O]+, 100), 
221(98), 220(98);  (M–H2O)+ C20H23O2N requires 309.1729 obsvd 309.1743. 
 
(R)-(-)- and (S)-(+)-2-(4-methoxyphenyl)propanoic acid 241 and 242.  
White solid, mp 74oC (MeOH) lit.:190 73-74oC.  [a]D27=-86.2 (c. 0.2, CH2Cl2) lit.:190 
[]D20=-59 (c. 0.3, EtOH) 241, []D27=+86.2 (c. 0.2, CH2Cl2) 242. 1H NMR, IR and 
MS as reported for corr. (S)-(+)-acid.175 
 
 
 
5.3 Preparation of enantiopure polyhydroxy -methyldeoxybenzoins by the one  
step Friedel-Crafts acylation 
Resorcinol (0.012g, 0.12 mmol) and enantiopure  2-aryl propionic acid (0.022g, 0.12 
mmol for 241) and BF3OEt2 (1 mL) were stirred at 70oC under argon atmosphere,  
until no starting material was observed on TLC-monitoring, and quenched with 2M 
HCl. The mixture was extracted with diethyl ether, washed carefully with water and 
dried with Na2SO4, filtrated and solvent evaporated to yield (R)- or (S)-1,2-
diarylpropan-1-ones as yellowish oils. After short column chromatography, 
recrystallisation yielded purified crystalline  -methyldeoxybenzoins ee 97 to 98%  as 
confirmed by chiral HPLC analysis (Table 4.). 
[2R]-(-)- and [2S]-(+)-1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)propan-1-one 
249 and 250.  
Flash chromatography ((7:1)CH2Cl2/EtOAC) yielded 249 (81%) and 250 (79%) as 
colourless oil, recrystallisation from aq. EtOH yielded light yellowish crystals; mp 
121-122oC (lit.:177 120-122oC, lit.:160 84oC for racemic angolensin). []D26=-115.0 (c. 
1.0, CH2Cl2) lit.:177 []D19=-115.0 (EtOH) 249, []D26=+115.0 (c. 1.0, CH2Cl2) 250; 1H 
NMR, 13C NMR, MS, IR and UV as reported for racemic angolensin.160  
 
 
 
 
 
5.4 Preparation of racemic polyhydroxy--methyldeoxybenzoins 244-246 
Racemic 2-(aryl)propionic acids 256a-d were prepared by the procedure previously 
described.35,191 The general procedure to prepare rac-polyhydroxy--
methyldeoxybenzoins 244-246 by a Friedel-Crafts acylation was as described for 
enantiopure derivatives in section 5.3.  
1-(2,4,-Dihydroxyphenyl)-2-(3,4-dihydroxyphenyl)-propan-1-one 244 
Flash chromatography (EtOAc) yielded 244 (80%) as a yellowish oil, recrystallization 
from aq. EtOH yielded light yellowish crystals; mp 90oC; d (500 MHz, d6-acetone) 
1.41 (3H, d, J 6.8, C(3)Me), 4.68 (1H, q, J 6.8, C(2)H), 6.29 (1H, d, J 2.4, C(3’)H), 
6.34 (1H, dd, J 8.6, 2.4, C(5’)H),  6.70 (1H, ddd, J 8.6, 2.2, 0.35, C(5”)H), 6.75 (1H, 
d, J 8.1, C(6”)H), 6.82 (1H, d, J 2.2, C(2”)H), 7.88 (1H, d, J 9.0, C(6’)H), 8.61 (1H, s, 
C(4’)OH),  12.9 (1H, s, C(2’)OH); d (125 MHz, d6-acetone) 19.4 (C3), 46.7 (C2), 
103.5 (C3’), 108.6 (C5’), 113.1 (C1’), 115.3 (2”), 116.4 (C6”), 119.8 (C5”), 134.1 
(C6’),  134.5 (C1”), 144.8 (C3”),146.1 (C4”), 165.3 (C2’), 166.6 (C4’), 204.8 (C1); 
m/z (EI) 274 (M+, 11%), 137(100); C15H14O5 requires 274.0841 obsvd 274.0853. 
 
1-(2,3,4-Trihydroxyphenyl)-2-(4-hydroxyphenyl)-propan-1-one 245   
Flash chromatography (EtOAc) yielded 245 (90%) as a yellowish oil, recrystallization 
from benzene yielded light yellowis crystals; mp 202oC; d (500 MHz, d6-acetone) 
1.43 (3H, d, J 6.8, C(3)Me), 4.78 (1H, q, J 6.8, C(2)H), 6.40 (1H, d, J 9.0, C(5’)H),  
6.77 (1H, d, J 8.6 C(3”)H), 6.77 (1H, d, J 8.6 C(5”)H), 7.19 (1H, d, J 8.6, C(2”)H), 
7.19 (1H, d, J 8.6, C(6”)H), 7.50 (1H, d, J 9.0, C(6’)H), 7.74 (1H, s, C(3’)OH), 8.61 
(1H, s, C(4’)OH),  12.9 (1H, s, C(2’)OH); d (125 MHz, d6-acetone) 19.4 (C3), 46.0 
(C2), 108.1 (C5’), 113.2 (C1’), 115.7 (C3”,5”), 123.7 (C6’),  129.3 (C2”,6”), 133.1 
(C4’), 133.6 (C1”), 152.3 (C3’), 153.6 (C2’), 157.1 (C4”), 206.8 (C1); m/z (EI) 274 
(M+, 29%), 153(100), 121 (34); C15H14O5 requires 274.0841 obsvd 274.0826. 
1-(2,3,4-Trihydroxyphenyl)-2-(3,4-dihydroxyphenyl)-propan-1-one 246   
Flash chromatography (EtOAc) yielded 246 (75%) as a yellowish oil, recrystallization 
from chloroform/EtOAc yielded off-white crystals; mp 113-115oC; d (500 MHz, d6-
acetone) 1.41 (3H, d, J 6.8, C(3)Me), 4.71 (1H, q, J 6.8, C(2)H), 6.40 (1H, d, J 9.0, 
C(5’)H),  6.70 (1H, ddd, J 8.6, 2.2, 0.35, C(5”)H), 6.75 (1H, d, J 8.1, C(6”)H), 6.82 
(1H, d, J 2.2, C(2”)H), 7.49 (1H, d, J 9.0, C(6’)H), 7.74 (1H, s, C(3’)OH), 8.61 (1H, s, 
C(4’)OH),  12.9 (1H, s, C(2’)OH); d (125 MHz, d6-acetone) 19.2 (C3), 46.8 (C2), 
103.9 (C3’), 111.8 (C1’), 115.4 (2”),116.0 (C6”), 116.3 (C6’),  119.7 (C5”),134.8 
(C1”), 138.5 (C5’), 144.9 (C3”),146.2 (C4”), 154.8 (C4’), 160.7 (C2’), 206.4 (C1); 
m/z (EI) 290 (M+, 20%), 153 (100), 137 (17); C15H14O6 requires 290.0790, obsvd 
290.0783. 
 
 
 
 
 
 	
 
5.5 General procedure for isoflavans 
Isoflavans 4, 15, 226-230 were synthesised by hydrogenation of the corresponding 
isoflavones over palladium on barium sulfate with vigorous stirring at room 
temperature.  Isoflavones (1 g) were dissolved in 96% ethanol (50 mL). 
Hydrogenation in the presence of 10% Pd/BaSO4 (1.6:1 [mol-eq.] isoflavone:Pd) was 
continued until no more hydrogen was consumed. Filtration and evaporation of the 
solvent yielded yellowish oils, which were crystallised from aq. EtOH. 
 
7-Hydroxy-4’-methoxyisoflavan 226 
White crystals 85% mp 153-155oC (from aq. ethanol) (lit.192  mp 160oC)  (500 MHz, 
d6-acetone) 3.96 (dd, J 10.4, 10.5, H-2 ax), 4.21 (ddd, J 10.5, 3.6, 2.0, H-2 eq), 3.12 
(dddd, J 10.5, 10.6, 5.7, 3.6, H-3 ax), 2.91 (ddd, J 15.6, 10.6, 1.0, H-4 ax), 2.86 (ddd, 
J 15.6, 5.7, 2.0, H-4 eq),  6.90 (d, J  8.2, H-5), 6.37 (dd, J 8.2, 2.5, H-6), 6.29 (d, J 
2.4, H-8), 7.26 (d, J 8.4, H-2’,6’) 6.91 (d, J 8.8, H-3’,5’), 8.12 (s, 7-OH), 3.79 (s, 4’-
OMe);  (125 MHz, d6-acetone) 71.5 (C-2), 38.8 (C-3), 32.6 (C-4), 131.0 (C-5), 108.9 
(C-6), 157.6 (C-7), 103.7 (C-8), 114.0 (C-4a), 156.0 (C-8a), 134.7 (C-1’), 129.3 (C-
2’,6’), 114.9 (C-3’,5’), 159.6 (C-4’), 55.5 (4’-OCH3); m/z (EI) 256 (M+, 85%), 149 
(13), 134 (100), 121 (20), 91 (10),77 (5), 65 (3), 51 (2); HRMS calcd for C16H16O3 
256.1099, found 256.1109. UV and IR as reported.88  
 
5,7-Dihydroxy-4’-methoxyisoflavan 227 
White crystals 84% mp 229-230oC (from aq. ethanol) (lit.84 mp 235-237oC);  (500 
MHz, d6-acetone) 3.92 (dd, J 10.4, 10.4, H-2 ax), 4.17 (ddd, J 10.4, 3.5, 2.1, H-2 eq), 
3.06 (dddd, J 10.4, 10.4, 5.5, 3.5, H-3 ax), 2.63 (dd, J 16.1, 10.4, H-4 ax), 2.91 (ddd, J 
16.1, 5.5, 2.0, H-4 eq), 5.88 (d, J 2.3, H-6), 6.29 (d, J 2.3, H-8), 7.27 (d, J 8.4, H-
2’,6’) 6.91 (d, J 8.8, H-3’,5’), 7.97 (s, 7-OH), 8.18 (s, 5-OH), 3.79 (s, 4’-OMe);  
(125 MHz, d6-acetone) 71.2 (C-2), 38.5 (C-3), 27.6 (C-4), 157.1 (C-5), 95.6 (C-6), 
157.6 (C-7), 96.0 (C-8), 102.1 (C-4a), 156.9 (C-8a), 135.1 (C-1’), 129.3 (C-2’,6’), 
114.8 (C-3’,5’), 159.6 (C-4’), 55.5 (4’-OCH3); m/z (EI) 272 (M+, 98%), 163 (30), 151 
(70), 134 (100), 121 (85), 119 (65), 91 (55); HRMS calcd for C16H16O4 272.1049, 
found 272.1057;  cm-1 3361, 1626, 1606, 1513, 1474, 1286, 1227, 1144, 1095, 1024, 
955.  
 
5,7,4’-Trihydroxyisoflavan 228 
White crystals 75% mp 213-214oC (from aq. ethanol) (lit.,104 mp 209-211oC);  (300 
MHz, d6-acetone) 3.89 (dd, J 10.5, 10.4, H-2 ax), 4.16 (ddd, J 10.4, 3.5, 2.1, H-2 eq), 
3.03 (dddd, J 10.5, 10.7, 5.4, 3.5, H-3 ax), 2.61 (dd, J 16.1, 10.7, H-4 ax), 2.90 (ddd, J 
16.1, 5.4, 2.0, H-4 eq), 5.88 (d, J 2.3, H-6), 6.03 (d, J 2.3, H-8), 7.17 (d, J 8.4, H-
2’,6’) 6.83 (d, J 8.5, H-3’,5’), 7.97 (s, 7-OH), 8.16 (s, 5-OH), 8.23 (s, 4’-OH);  (75 
MHz, d6-acetone) 71.3 (C-2), 38.5 (C-3), 27.6 (C-4), 157.1 (C-5), 95.6 (C-6), 157.5 
(C-7), 95.8 (C-8), 102.1 (C-4a), 156.8 (C-8a), 133.9 (C-1’), 129.3 (C-2’,6’), 116.2 (C-
3’,5’), 157.1 (C-4’); m/z (EI) 258 (M+, 83%), 246 (15), 163 (20), 139 (100), 120 (80), 
107 (15), 91 (10), 69 (7); HRMS calcd for C15H14O4 258.0892, found 258.0903;  cm-1 
3373, 1611, 1514, 1471, 1380, 1220, 1095, 1043, 1020, 962.  
 
 
 $
7,4’-Dihydroxyisoflavan 15 
White needles 88% mp 160oC (from benzene) (lit.,193158oC);  (500 MHz, d6-acetone) 
3.90 (dd, J 10.5, 10.5, H-2 ax), 4.18 (ddd, J 10.5, 3.6, 2.1, H-2 eq), 3.07 (dddd, J 10.5, 
10.6, 5.7, 3.6, H-3 ax), 2.89 (ddd, J 15.6, 10.6, 1.0, H-4 ax), 2.84 (ddd, J 15.6, 5.7, 
2.0, H-4 eq), 6.89 (d, J 8.2, H-5), 6.37 (dd, J 8.2, 2.4, H-6), 6.29 (d, J 2.4, H-8), 7.16 
(d, J 8.6, H-2’,6’) 6.82 (d, J 8.5, H-3’,5’), 8.07 (s, 7-OH), 8.21 (s, 4’-OH);  (125 
MHz, d6-acetone) 71.6 (C-2), 38.8 (C-3), 32.7 (C-4), 131.0 (C-5), 108.9 (C-6), 157.6 
(C-7), 103.7 (C-8), 114.1 (C-4a), 156.0 (C-8a), 133.5 (C-1’), 129.2 (C-2’,6’), 116.3 
(C-3’,5’), 157.2 (C-4’); MS as reported.194;  cm-1 3348, 1614, 1599, 1513, 1454, 
1242, 1120, 1021, 827. 
 
 
Isoflavan 4 
White powder 80% mp 55-56oC (from aq. ethanol) as previously reported.195  (500 
MHz, d6-acetone) 4.06 (dd, J 10.5, 10.5, H-2 ax), 4.30 (ddd, J 10.5, 3.7, 2.0, H-2 eq), 
3.22 (dddd, J 10.5, 10.3, 5.6, 3.7, H-3 ax), 3.08 (dd, J 16.1, 10.3, H-4 ax), 2.98 (ddd, J 
16.1, 5.6, 1.7, H-4 eq), 7.09 (m, H-5), 6.85 (td, J 7.1, 1.2, H-6), 6.79 (dd, J 8.7, 1.2 H-
8), 7.38 (m, H-2’,5’, 6’), 7.35 (m, H-3’,5’), 7.28 (m, H-4’);  (125 MHz, d6-acetone) 
71.2 (C-2), 39.3 (C-3), 33.0 (C-4), 130.7 (C-5), 121.0 (C-6), 127.8 (C-7), 117.1 (C-8), 
123.0 (C-4a), 155.3 (C-8a), 142.6 (C-1’), 129.5 (C-2’,6’), 128.3 (C-3’,5’), 128.0 (C-
4’); IR as reported.193 m/z (EI) 210 (M+, 100%), 149 (12), 119 (76), 104 (56), 91 (28); 
HRMS calcd for C15H14O 210.1045 , found 210.1029. 
 
5,7,3’,4’-Tetrahydroxyisoflavan 229 
White crystals 70% mp 220oC (from aq. ethanol);  (300 MHz, d6-acetone) 3.87 (dd, J 
10.3, 10.5, H-2 ax), 4.14 (ddd, J 10.3, 3.2, 2.0, H-2 eq), 3.00 (dddd, J 10.5, 10.8, 5.4, 
3.2, H-3 ax), 2.58 (dd, J 16.1, 10.8, H-4 ax), 2.88 (ddd, J 16.1, 5.4, 1.5, H-4 eq), 5.87 
(d, J 2.2, H-6), 6.02 (d, J 2.0, H-8), 6.82 (s, H-2’), 6.63 (dd, J 8.1, 2.1, H-5’), 6.80 (d, 
J  8.1, H-6’), 8.17 (s, 5-OH), 7.97 (s, 7-OH), 7.79 (s, 3’-OH), 7.84 (s, 4’-OH);  (75 
MHz, d6-acetone) 71.4 (C-2), 38.7 (C-3), 27.6 (C-4), 157.1 (C-5), 95.6 (C-6), 157.5 
(C-7), 95.9 (C-8), 102.2 (C-4a), 156.9 (C-8a), 134.8 (C-1’), 115.3 (C-2’,6’), 144.8 (C-
3’), 146.0 (C-4’), 119.5 (C-5’), 116.2 (C-6’); m/z (EI) 258 (M+, 83%), 246 (15), 163 
(20), 139 (100), 120 (80), 107 (15), 91 (10), 69 (7); m/z (EI) 274 (M+,55%), 167 (10), 
139 (100), 123 (15); HRMS calcd for C15H14O5 274.0841, found 274.0853.  
 
5,7-Dihydroxy-3’,4’-dimethoxyisoflavan 230 
White crystals 75% mp 208-209oC (from aq. ethanol);  (500 MHz, d6-acetone) 3.93 
(dd, J 10.4, 10.4, H-2 ax), 4.19 (ddd, J 10.4, 3.6, 2.1, H-2 eq), 3.05 (dddd, J 10.4, 
11.1, 5.5, 3.6, H-3 ax), 2.65 (dd, J 16.1, 11.1, H-4 ax), 2.91 (ddd, J 16.1, 5.5, 2.0, H-4 
eq), 5.88 (d, J 2.3, H-6), 6.03 (d, J 2.3, H-8), 6.98 (d, J 2.0, H-2’) 6.86 (d, J 8.2, 2.0, 
H-3’,5’), 6.91 (d, J 8.2, H-6’ ), 7.95 (s, 7-OH), 8.16 (s, 5-OH), 3.79 (s, 3’-OMe), 3.82 
(s, 4’-OMe);  (125 MHz, d6-acetone) 71.2 (C-2), 38.9 (C-3), 27.6 (C-4), 157.1 (C-5), 
95.6 (C-6), 157.6 (C-7), 95.9 (C-8), 102.1 (C-4a), 156.9 (C-8a), 135.8 (C-1’), 112.5 
(C-2’), 149.3 (C-3’), 150.5 (C-4’), 120.2 (C-5’), 113.1 (C-6’), 56.1 (3’, 4’-OCH3); m/z 
(EI) 302 (M+, 65%), 164 (100), 151 (34), 121 (10); HRMS calcd for C17H18O5 
302.1154, found 302.1140. 
 
 

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